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ABSTRACT
The Acute Effects of Transdermal Testosterone Precursor Administration 
on Serum Steroid Hormone Levels in Females
by
Mark Anthony Rasmussen
Dr. Lawrence Golding, Examination Committee Chair 
Distinguished Professor of Kinesiology 
University o f Nevada, Las Vegas
Most governing sports authorities have banned the use of anabolic steroids as 
ergogenic aids. Recently, a transdermal testosterone precursor dietary supplement 
(AndrosteDERM®) has become available; athletes can apply the cream to their skin with 
the belief that it w ill increase serum testosterone levels, muscle mass, and strength. The 
purpose of this study was to measure the effects of one m illiliter of AndrosteDERM® 
applied to the inner surface of the upper arm on the serum levels of androstenedione, and 
free and total testosterone in female subjects. Serum levels were measured before 
application and every 45 minutes thereafter for six hours. Serum androstenedione, and 
free and total testosterone levels were analyzed using radioimmunoassay. Although the 
trend seemed to indicate that serum levels did not rise after application, several subjects 
had physiologically impossible values, which appear to be due to methodological errors. 
That information, along with the initial small number of subjects made the use of 
statistical treatment unwise and inferences about the population impossible.
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CHAPTER 1 
INTRODUCTION
Athletes often use ergogenic aids in an attempt to gain an edge over their 
competitors. An ergogenic aid can be defined as any substance or technique used to 
improve athletic performance (Brooks, Fahey, White, & Baldwin, 2000). In ancient 
times, athletes and soldiers would consume specific animal parts to obtain the strength, 
speed, or agility associated with that animal (Brooks et al., 2000). Today, the use of 
ergogenic aids in sports is universal. Dietary supplements are some o f the most popular 
and widely used of all ergogenic aids. The use of dietary supplements, including amino 
acids, caffeine, creatine, and protein powders is prevalent in almost every sport today, in 
both males and females.
Recently, dietary supplementation of androstenedione, a precursor to the hormone 
testosterone, has gained interest as a method to improve performance by increasing 
muscle mass and strength. Many of the manufacturers of dietary supplements have 
started to market new products known as testosterone precursors, or “prohormones” , with 
androstenedione being the most popular. Prohormones are marketed with the claim that 
their use w ill cause an increase in endogenous testosterone production, acting in much 
same way as anabolic steroids (McArdle, Katch, & Katch, 1999). When anabolic 
steroids are added to athletes’ training, increases in muscle size and strength and gains in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
total and lean body mass have been reported (Stamford & Moffatt, 1974; Friedel, Dettori, 
Hannan, Patience, & Plymate, 1991; Bhasin, Storer, Berman, Callegari, Clevenger, 
Phillips, Bunnell, Tricker, Shirazi, & Casaburi, 1996).
To date, very little research has been conducted on the effectiveness of 
testosterone precursor supplementation. Most of the research has investigated oral 
androstenedione supplementation, with mixed results. Some studies have shown an 
increase in testosterone levels in the body (Earnest, Olson, Broeder, Breuel, & Beckham, 
2000; Leder, Longcope, Gatlin, Ahrens, Schoenfeld, & Finkelstein, 2000), while most 
others have not (Ballantyne, Phillips, MacDonald, Tamopolsky, & MacDougall, 1999; 
Brown, Kohut, Franke, Jackson, Vukovich, & King, 1999; Brown, Reifenrath, Uhl, 
Sharp, & King, 1999; King, Sharp, Brown, Reifenrath, & Uhl, 1999; King, Sharp, 
Vukovich, Brown, Reifenrath, Uhl, & Parsons, 1999; Parsons, Sharp, Brown, Reifenrath, 
Uhl, & King, 1999; Quindry, Brittingham, Panton, Breuel, Earnest, Olson, & Broeder, 
1999; Rasmussen, Volpi, Gore, & Wolfe, 2000; Reifenrath, Sharp, Brown, Uhl, & King, 
1999; Wallace, Lim, Cutler, & Bucci, 1999). None o f the studies have investigated the 
effects of testosterone precursor supplementation in females.
Recently, new methods of testosterone precursor delivery have been developed, 
which are touted to be superior to oral ingestion. Sublingual and transdermal versions of 
testosterone precursors are now available. The benefits o f these new delivery methods 
include absorption directly into the bloodstream, thus bypassing the rapid initial 
breakdown in the liver, and faster action because of the absorption directly into the 
bloodstream. One such product is the transdermal version AndrosteDERM®, which 
contains the testosterone precursors androstenedione and androstenediol.
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Purpose of the Study 
The purpose of this study was to evaluate the acute effects of transdermal 
testosterone precursor supplement (AndrosteDERM®) administration on the serum 
steroid hormone levels of androstenedione and free and total testosterone in females.
Need for the Study
Testosterone precursor supplements are very popular and widely used by athletes 
of both sexes, in many different sports. Studies to date have been inconclusive as to 
whether or not these supplements have any ergogenic effects. To date, no studies have 
investigated the effects of testosterone precursor administration in females. The effects 
of a transdermal delivery method also have not been tested.
Limitations
1. Since the sample size was small, seven subjects, and homogeneous, college- 
aged females, the generalization of the results should be done with caution.
2. Because some o f the results obtained from the radioimmunoassay procedure are 
in question, the concentrations of serum androstenedione and free and total 
testosterone may not be exact.
3. AndrosteDERM® is one of several different types of testosterone precursors. 
The results obtained from using another type o f testosterone precursor or 
another delivery system may be different.
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Assumptions
1. Participants had normal baseline androstenedione and free and total 
testosterone levels for females.
2. AndrosteDERM® was absorbed into the bloodstream in 6 hours.
Statement of Hypotheses
Null Hypotheses
Ho: Acute AndrosteDERM® administration w ill not increase serum androstenedione
levels within six hours of application.
Ho: Acute AndrosteDERM® administration w ill not increase serum free testosterone
levels within six hours of application.
Ho: Acute AndrosteDERM® administration w ill not increase serum total testosterone
levels within six hours of application.
Alternate Hypotheses
Hi : Acute AndrosteDERM® administration w ill increase serum androstenedione
levels within six hours of application.
Hi : Acute AndrosteDERM® administration w ill increase serum free testosterone
levels within six hours of application.
Hi : Acute AndrosteDERM® administration w ill increase serum total testosterone
levels within six hours of application.
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CHAPTER 2
LITERATURE REVIEW
Anabolic Steroids and Testosterone 
Anabolic steroids are synthetic derivatives of the male sex hormone testosterone. 
Anabolic steroids can be defined as steroids whose function is to stimulate protein 
synthesis (Ariel, 1972). Because anabolic steroids have inseparable anabolic and 
androgenic properties, they should correctly be called anabolic-androgenic steroids. It is 
the anabolic effects, such as anticatabolism, enhanced neural conduction, and increased 
skeletal muscle mass that are desired by those who use them, and the androgenic, or 
masculinizing, effects that lead to the undesirable side effects (Fahey, 1998; Blue and 
Lombardo, 1999). Since the 1940’s attempts have been made to synthesize a steroid that 
is completely anabolic, without any of the unwanted androgenic side effects (Blue and 
Lombardo, 1999). To date, all attempts have failed. The anabolic and androgenic effects 
of these drugs are not due to different actions, but instead result from the interaction of 
the drug with the same receptor molecule in different tissues (Wilson, 1988).
Testosterone is produced endogenously in the interstitial cells o f Leydig in the 
testes (Blue and Lombardo, 1999). Like all steroid hormones, testosterone is synthesized 
from cholesterol. Loebel and Kraemer (1999) indicated that the rate-limiting step in the 
synthesis of testosterone is the conversion o f cholesterol to pregnenolone, which takes
5
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place in the mitochondria. According to Lamb (1989) and Hough (1990), the testes 
secrete between 4 and 10 mg/day of testosterone in normal adult males. Mean 
testosterone production in males is approximately 8 mg/day (George, 1988). The plasma 
concentration of testosterone in males is approximately 3-9 ng/ml, of which, 95% or 
more is secreted by the testes (Gard, 1998). In females, the plasma testosterone 
concentration is 0.2-0.7 ng/ml (Gard, 1998), all of which is produced by the ovaries and 
the adrenal glands (Schânzer, 1996), primarily the adrenal glands (Laycock & Wise, 
1996).
Testosterone (Figure 1) is secreted after receiving a signal from luteinizing 
hormone, which is secreted from the pituitary gland (Alen & Rahkila, 1988). Loebel and 
Kraemer (1999) state that the hypothalamus secretes luteinizing hormone-releasing 
hormone, which causes luteinizing hormone to be released from the anterior pituitary 
gland. The amount of luteinizing hormone secreted from the pituitary gland is controlled 
by the amount of testosterone in the blood via a negative feedback loop (Brooks, 1983).
Testosterone is responsible for the normal growth and development of the male 
sex organs and maintenance of secondary sexual characteristics, including facial, pubic, 
chest, and axillary hair growth, enlargement o f the larynx, sperm production, and 
alterations in body musculature and fat distribution (Fahey, 1998; Blue & Lombardo, 
1999). Testosterone is also responsible for the greater muscle mass in men when 
compared to women (Wyiui, 1975). In both males and females, testosterone increases 
libido (Goodman, 1994). Testosterone in females is responsible for some secondary 
sexual characteristics, including pubic and axillary hair growth (George, 1988).
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TESTOSTERONE
Figure I; Testosterone Chemical Structure
The most active form o f testosterone is the free, unbound form, which accounts 
for 2% of the total testosterone in the body (Loebel & Kraemer, 1999). Testosterone 
bound to albumin accounts for 38% o f the total testosterone; the remaining 60% is bound 
to sex hormone-binding globulin (Loebel & Kraemer, 1999). It is the testosterone that is 
not bound to sex hormone-binding globulin that is available for metabolism (Loebel & 
Kraemer, 1999).
Testosterone is rapidly metabolized by the enzyme SP-reductase (Goodman,
1994) in the liver, into various I7-keto steroids, mainly androstenedione and then to 
either androsterone or one of its two isomers, epiandrosterone or etiocholanone (George, 
1988). The liver is the main site of testosterone degradation, with the subsequent release 
of water soluble sulfates (Goodman, 1994) and testosterone glucuronide (Hackney, 1998) 
into the blood for excretion in the urine (Goodman, 1994). When taken orally.
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8testosterone is absorbed into the portal blood circulation and is rapidly degraded by the 
liver, leading to insignificant amounts reaching systemic circulation (Wilson & Griffin, 
1980). Testosterone that is injected intramuscularly is rapidly absorbed from the 
injection site and degraded (Wilson & Griffin, 1980). Therefore, modifications have 
been made to the testosterone molecule to alter its metabolism and get around these 
complications. In order for serum testosterone levels to be maintained (during 
replacement therapy), testosterone esters are injected intramuscularly, or slowly 
metabolized oral derivatives are ingested (Wilson & Griffin, 1980).
Three general types of modifications have been created, estérification of the 1?P- 
hydroxyl group, alkylation of the 17a- position, and a modification of the ring structure 
(Wilson & Griffin, 1980). Estérification of the 17P-hydroxyl group prolongs the 
duration of time the steroid is active, thus augmenting the effects (Wilson & Griffin, 
1980). The more carbon molecules in the acid ester, the more prolonged the action of the 
anabolic steroid (Wilson & Griffin, 1980). Forbes (1985) stated that nitrogen balance 
studies have demonstrated that intramuscular anabolic steroids have more prolonged and 
greater effects. A 17-a methyl or -ethyl group is common on most orally active anabolic 
steroids (Wilson & Griffin, 1980). The 17a-alkylation of an orally active anabolic 
steroid slows the breakdown by the liver; for this reason, all I7a-alkylated anabolic 
steroids are toxic to the liver (George, 1988). Some substitutions made to the 2,9, and 11 
carbons of the testosterone molecule (ring structure) also appear to enhance anabolic 
activity (Wilson & Griffin, 1980). It could be reasoned that because exogenous 
testosterone must be modified to exhibit any sustained effects on the body, an unmodified
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
precursor to testosterone such as androstenedione or androstenediol would meet a similar 
fate as unmodified testosterone (rapid metabolism by the liver).
Medicinally, anabolic steroids have been used to treat a variety of disorders in the 
body including male hypogonadism, certain anemias, bone marrow failure, breast cancer 
in postmenopausal women, hereditary angioneurotic edema, osteoporosis, and disorders 
where catabolism and negative nitrogen balance are favored, such as wasting illnesses 
and patients recovering from severe trauma or surgery (Wilson & Griffin, 1980; Wilson, 
1988; Hough, 1990). Haupt and Rovere (1984) report that anabolic steroids were first 
given to German troops during World War II to increase their aggression. At about the 
same time, anabolic steroids were also used for their ability to restore positive nitrogen 
balance in starvation victims (Ryan, 1981). Hough (1990) indicated that athletes first 
used anabolic steroids in 1953. In 1954, a Russian team physician told Dr. John Zeigler, 
a physician for the United States Weightlifting team, that the Russian weightlifters were 
using anabolic steroids to augment their training (Street, Antonio, & Cudlipp, 1996).
One year later. Dr. Zeigler developed methandrostenolone (Dianabol) and introduced it to 
the United States weightlifting team (Street et al., 1996). In 1968, the International 
Olympic Committee placed anabolic steroids on its list of banned substances (Hough, 
1990). Since that time anabolic steroids use has become very popular in sports. They 
were initially used mainly by power athletes, those involved in football, weightlifting, 
and field events (shot put and hammer throw). Now, their use is seen in sports that do not 
rely as heavily on power, including baseball and tennis. Some (Haupt & Rovere, 1984) 
believe that anabolic steroid use by athletes has reached almost epidemic proportions in 
most sports. Athletes use anabolic steroids in the belief that they w ill increase body and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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muscle mass, muscular strength and aggressiveness (Hough, 1990; Fahey, 1998). Wade 
(1972) stated that winning at the Olympics has become a question of which country has 
the best doctors and chemists.
Anabolic Steroid Research 
Since athletes first used anabolic steroids, there has been great debate whether 
they actually improve performance (Wagner, 1991). In an attempt to determine whether 
or not anabolic steroids improve performance, researchers have studied their effects, with 
mixed results. The majority of anabolic steroid research was performed during the 
1970’s. Most early studies were of poor quality and had mixed results (Wagner 1991; 
Blue & Lombardo, 1999). The scientific studies are fraught with methodological 
problems that make interpretation difficult and comparisons between studies confusing 
(Lombardo, 1993). Ryan (1981) stated that conclusions were drawn that were not 
justified by the results obtained.
A great deal o f criticism has been made involving early anabolic steroid studies 
(American College of Sports Medicine, 1987). The studies that demonstrated no 
increases in muscular strength have been criticized because of the use o f inexperienced 
participants, lack o f dietary (calories and protein) control, low-intensity training, and non­
specific measuring o f strength (American College of Sports Medicine, 1987). The 
studies that have demonstrated increases in muscular strength have been criticized for 
low numbers of participants, improper statistical designs, inadequate execution, and 
unsatisfactory reporting of the results (American College of Sports Medicine, 1987). A 
meta-analysis of the studies from 1966 to 1990 performed by Elashoff, Jacknow, Shain,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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& Braunstein (1991) assessed the effects o f anabolic steroids on human muscular 
strength. Thirty studies were reviewed in which subjects received more than one dose of 
the anabolic steroid studied and in which changes in muscular strength were measured.
Of the 30 studies, 14 were determined to be of poor quality for various reasons (Elashoff 
et al., 1991). A ll of the studies differed in regards to the length of time of anabolic 
steroid administration, the intensities of strength training programs, the pre-training levels 
of strength in the participants, and especially the dosages of anabolic steroids 
administered (Alen & Hâkkinen, 1987; Lombardo, 1993).
The weight training experience of the participants is an important factor to 
consider (Lombardo, 1993). Alen and Hâkkinen (1987) explained that anabolic steroids 
do not accelerate the physical development of athletes in the very early phase of strength 
training because the strength training itself is enough of a stimulus to produce substantial 
gains during that phase. Inexperienced weightlifters w ill make large gains at the 
beginning o f any weight training program; these large gains are not significantly 
increased by anabolic steroids in the early part o f their training (Lombardo, 1993).
Blue and Lombardo (1999) stated that at therapeutic doses, anabolic steroids do 
not enhance muscle strength or athletic performance. Endogenous testosterone 
production is depressed, and the net effect is negligible (Blue & Lombardo, 1999). 
According to Percy (1978), Lamb (1984 and 1989), Taylor (1987), Elashoff et al. (1991), 
and (Wagner, 1991) one obvious flaw with past anabolic steroid research, is that the 
amount of the anabolic steroids administered in most clinical studies has been well below 
the massive doses taken by athletes. The dosages o f anabolic steroids taken by most 
athletes are 10 to 200 times greater than normal therapeutic doses, in an attempt to
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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maximize the anabolic effects (Street et al., 1996; Blue & Lombardo, 1999). Casaburi, 
Storer, and Bhasin (1996) stress that the doses of anabolic steroids used in studies are low 
considering, 1) all testosterone derivatives are less potent than testosterone; 2) 
approximately 7mg of testosterone are produced daily in healthy males; 3) the absorption 
of oral anabolic steroids is erratic and incomplete; 4) some of the orally administered 
anabolic steroid is metabolized by the liver during the first pass through. Taylor (1987) 
and Wilson (1988) noted that scientific research also does not involve the administration 
o f anabolic steroids in the stacking and cyclical fashions utilized by many athletes. Lamb 
(1989) and Wagner (1991) stated that it is medically unethical to administer anabolic 
steroids in the dosages used by athletes. Very few definitive, controlled clinical trials 
with supraphysiological doses of anabolic steroids have been conducted (Bardin, 
Swerdloff, & Santen, 1991).
Further research has also been hampered by the problems o f conducting a true 
double-blind study (Lamb, 1989; Wagner, 1991). A double blind study to investigate the 
effects of anabolic steroids would be ideal, but many athletes can recognize when they 
are on the anabolic steroid compared to the placebo (Lamb, 1989). In a study by Freed, 
Banks, Longson, and Burley (1975), all thirteen participants guessed correctly when they 
were on the steroid and the placebo portions o f the study. Lamb (1984) and Taylor 
(1987) concluded that because of the lack of a satisfactory placebo and the usually low 
steroid doses that are used in research studies, great care should be considered when 
evaluating scientific evidence that deals with anabolic steroid use in athletes. The studies 
that appear in the literature are of limited value in assessing the effects o f the drugs used 
(Fahey & Brown, 1973; Taylor, 1987).
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Studies that Found Ergogenic Benefits 
Papanicolaou and Falk (1938) were some of the first to note that androgenic 
hormones (testosterone propionate) have a stimulating effect on the muscles, producing 
hypertrophy after long-term administration. During the 1960’s and 70’s, researchers 
attempted to perform studies that investigated the effects of anabolic steroids on muscle 
strength and body composition (Taylor, 1987). The difficulties encountered during this 
process have already been mentioned. In most studies in which trained athletes took 
steroids in relatively low doses for short periods of time and also used weight training 
and proper diet, a significant increase in skeletal muscle mass and muscle strength was 
noticed in many subjects (Taylor, 1987). Despite the problems with the scientific data, it 
is commonly accepted on the part o f athletes, coaches, sport physicians, and the public 
that anabolic steroids improve athletic performance (Bardin et al., 1991). While many of 
the studies were not double-blinded or placebo controlled, it has to be concluded that 
anabolic steroids, in high doses combined with heavy resistance training w ill result in 
increased body weight and muscle size (MacDougall, 1983).
Johnson and O’Shea (1969) studied the effects of an anabolic steroid on strength 
development. In what was planned to be a double blind study (only twelve men were 
willing to take the steroid and thus became the experimental group), twelve pairs of 
participants were fed protein supplements and trained with weights for six weeks. During 
the first three weeks, all participants were treated identically with the same weight 
training program and protein supplements. During the last three weeks o f the study, the 
experimental group received 10 mg/day of methandrostenolone. The results indicated 
that both dynamic and static strength and body weight increased significantly in the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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that both dynamic and static strength and body weight increased significantly in the 
experimental group. The increased body weight occurred with no significant changes in 
subcutaneous adipose tissue, leading the investigators to believe that the weight gained 
was lean body mass and not body fat. Surprisingly, maximum oxygen uptake increased 
significantly, even though the training program was not designed to promote 
cardiovascular fitness. The researchers concluded that the combination of anabolic 
steroids, high protein intake, and heavy weight training accelerated protein synthesis and 
increased static and dynamic muscle strength and body weight.
O’Shea and Winkler (1970) studied the effects of an anabolic steroid 
(oxandrolone) on the physical factors involved with sport-specific training in highly- 
advanced swimmers and weightlifters. Double blind testing was not used for this study 
because of the small number of participants. During the first six weeks of the eleven- 
week study, subjects were given 10 mg/day of oxandrolone (treatment period) and a 
protein supplement; during the final five-week washout period, no anabolic steroids were 
administered. The results of this study indicated that body weight increased in all 
participants. An increase in protein utilization was also demonstrated in eight of the 
eleven participants. In the group of swimmers, no improvement was noted in 
performance (swimming speed), while muscle strength improved dramatically in the 
group of weightlifters. The investigators concluded that muscular strength is increased 
when anabolic steroids are combined with a high protein diet and heavy weight training. 
The investigators also considered that because the weightlifters knew they were receiving 
anabolic steroids, the degree to which the strength increases can be attributed to the 
steroids rather than psychological effects cannot be distinguished.
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Ward (1970) investigated the effects of an anabolic steroid (10 mg/day of 
methandrostenolone), in conjunction with heavy weight training on maximum strength 
(standing press, squat, and bench press), maximum oxygen uptake, lean body mass, and 
blood volume in one experienced weightlifter. Maximum strength in all three exercises 
increased significantly (35 lbs, 12.73% in the standing press, 50 lbs, 10.75% in the squat, 
and 35 lbs, 9.09% in the bench press). Maximum oxygen uptake (in the absence of 
cardiovascular training) increased 15.66% when measured in aerobic capacity, and 
12.97% when measured in aerobic power. Lean body mass increased 18 lbs, while body 
fat decreased 9 lbs (4%). Blood volume was not changed. The author concluded that 
anabolic steroids may be beneficial in increasing muscle strength, lean body mass, and 
possibly aerobic endurance.
O’Shea (1971) studied the effects of an anabolic steroid on the muscular strength 
levels of twenty male weightlifters. The participants were divided into a placebo and a 
steroid group (10 mg/day of methandrostenolone); the diets of all participants were 
augmented with a protein supplement. The weight training program employed in this 
study was identical for all participants, and was noted as being very intense. The results 
of this study indicated that maximum bench press and squat strength increased 
significantly in the group who received anabolic steroids. Body weight in the steroid 
group also increased significantly. When a skinfold measurement was taken at the waist, 
no increase was noted, indicating the weight gained was lean body mass, and not adipose 
tissue. The researchers concluded that anabolic steroids do increase dynamic strength in 
competitive athletes, but that this is very dependant on the type and the quality o f both 
the training (heavy weightlifting) and the diet (high protein) consumed.
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The physiological effects of the anabolic steroid, methandrostenolone, were 
studied by Ariel in 1972. In the first seven weeks of a fifteen-week study, the six 
participants trained with weights five days a week (training period). From the eighth to 
the eleventh week of the study, all participants were given a placebo and were told it 
contained 10 mg of methandrostenolone (placebo period). From the twelfth to the 
fifteenth week of the study, three of the participants received 10 mg of 
methandrostenolone (experimental group), while the other three participants continued to 
receive the placebo (anabolic steroid period). Significant increases in muscle strength 
were noticed in the experimental group between the placebo period and the anabolic 
steroid period. The investigator concluded that the experimental group was able to exert 
greater maximum muscular contractile force during the anabolic steroid period when 
compared to the placebo period and to the control group, whose progress did not increase 
significantly.
The effects of the anabolic steroid methandrostenolone on strength and aerobic 
capacity were studied by Bowers and Reardon (1972). Eighteen weightlifters 
volunteered for this six-week study, and were divided into an experimental (steroid) and a 
control (placebo) group. A ll subjects received daily protein supplementation; the steroid 
group received 10 mg/day o f methandrostenolone for the last twenty-one days of the 
study. The results of the study showed that the experimental group significantly 
increased strength in the bench press and squat, body weight and bicep and forearm girth 
over the control group. No increases were seen in aerobic capacity.
Johnson, Fisher, Silvester, and Hofheins (1972) studied the effects o f an anabolic 
steroid (methandrostenolone) on muscular strength, body weight, oxygen uptake and
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spermatogenesis. A ll subjects began an identical seven-week weight-training program; at 
the end of the fourth week, 24 o f the 31 subjects were randomly placed into either the 
control (placebo) group, or the treatment (10 mg/day o f the anabolic steroid) group. In 
addition, all subjects supplemented their diet with a protein supplement. The results 
showed no significant increase in maximum oxygen uptake, and no changes in sperm 
count. In the treatment group, strength increased and the gains in body weight were 
significant over the placebo group. The investigators concluded that anabolic steroid 
supplementation does significantly improve muscle size and strength when accompanied 
with a high protein diet and intensive weight training.
Ward (1972) investigated the effects of an anabolic steroid on maximum strength 
and lean body mass. Sixteen healthy male weight trainers volunteered for the five-week 
study. The participants were divided into an experimental group (10 mg/day of 
methandrostenolone) and a placebo group. The results indicated that the experimental 
group improved in maximum strength and gained more lean body mass than the control 
group. The experimental group had a significant increase in body mass, and a significant 
reduction in body fat, with no increase in body weight above the control group. The 
author concluded that the use of anabolic steroids may produce significant increases in 
strength and lean body mass in athletes involved in a heavy weight training program 
beyond what would result from heavy weight training alone.
Ariel (1973) investigated the effect on an anabolic steroid on maximum skeletal 
muscle contractile force. Six male weightlifters volimteered for this eight-week double 
blind study. The participants were divided into an experimental group (10 mg/day of a 
placebo from weeks two through four and the steroid from weeks four through eight) and
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a placebo group (placebo administered weeks two through eight). The results indicated 
that the experimental group was able to exert greater maximum muscle contractile force 
during the anabolic steroid period when compared to the placebo period and the control 
group, who did not significantly improve performance. The rate of progress of the 
experimental group was higher during the anabolic steroid period when compared to the 
control group.
Brown and Tait (1973) interviewed a number of athletes who were self- 
administering various dosages and types of anabolic steroids. A ll reports of strength and 
weight increases were subjective and reported by the athletes themselves. The weight 
gained was highly variable; three athletes gained no weight, while one gained 40 and 
another SO lbs. Seven athletes gained strength, while two did not. Most o f the athletes 
who reported strength gains said they were dramatic; one increased his maximum deadlift 
110 lbs, another gained 90 lbs on his maximum squat. It was concluded that anabolic 
steroids may increase strength development when accompanied by a healthy diet and a 
heavy weight training program.
Ariel (1974a) investigated the prolonged effects of an anabolic steroid on muscle 
strength following cessation of treatment and a 15-week detraining period. College-aged 
male participants were divided into two groups, the experimental group who received 15 
mg of methandrostenolone daily for four weeks, or the control group who received 
nothing. Following the four weeks of anabolic steroid treatment, the drug was removed 
and weight training ceased (15 weeks of detraining). Maximum strength was tested in 
the bench press, military press and the squat in all participants. Following the 15 weeks 
of detraining, muscle strength was tested again in all participants. In the bench press, the
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experimental group lost a not statistically significant 6.6 kg of strength, while the control 
group lost a significant 19.9 kg. In the military press, the experimental group lost a not 
statistically significant 4.76 kg of strength, while the control group lost a significant 9.52 
kg. In the squat, the experimental group lost 8.44 kg (not statistically significant), while 
the experimental group lost 15.19 kg, which again was significant. This study indicated 
that participants who were involved in strength training without anabolic steroids lost a 
significant amount o f strength following detraining, while the participants who trained 
with anabolic steroids were better able to maintain their strength levels following 
detraining.
Ariel (1974b) investigated the residual effects o f anabolic steroid administration 
on muscular force following cessation. Ten male weight lifters were divided into two 
groups, one who received the anabolic steroid (15 mg of methandrostenolone daily) first, 
followed by an identical placebo (Group 1), or one who received the placebo first, then 
the anabolic steroid (Group 2). A ll participants underwent an identical weight training 
protocol. The results indicated that anabolic steroids enhanced muscular strength, and the 
rate of increase of muscular strength. Following the administration of the anabolic 
steroid, there was a dramatic decrease in the muscular strength gained. Group 1 showed 
significant strength gains while using the anabolic steroid, but following cessation of the 
steroid, no significant gains in muscular strength were found. During the placebo period 
in Group 2 (the first part o f the study), significant gains in three o f the four weight 
training exercises were demonstrated; during the anabolic steroid period for Group 2, 
significant gains in muscular strength were seen in all participants in all weight training 
exercises.
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O’Shea (1974) studied the effects of stanozolol (an anabolic steroid) on adrenal, 
liver, and muscle function in men. Eighteen weightlifters were equally divided into two 
groups, a treatment (stanozolol) and a placebo group, for the five-week study.
Participants in the treatment group were given 8 mg/day of stanozolol; all participants 
supplemented their diets with a protein supplement and participated in an identical weight 
training program. When the biochemical data was evaluated, no significant alterations 
were noted in regards to adrenal, liver, or muscle function. When body weight and 
muscle strength were measured, the treatment group increased significantly in regards to 
muscle strength, but the body weight gained was not significant. The investigator 
theorized that anabolic steroids, when supplemented with a high protein intake and an 
intense weight training program, promote significant increases in dynamic muscular 
strength.
The purpose of the Stamford and Moffatt (1974) study was to approximate the 
actual conditions under which athletes use anabolic steroids. The controlled conditions 
included the administration of more than the recommended dosage o f anabolic steroids, a 
high protein diet, and an intense weight training program. Twenty-four male 
weightlifters all underwent an identical weight training program, for four weeks. After 
the initial four week period, the participants were divided into four groups. Group 1 
received 20 mg o f methandrostenolone and a protein supplement daily. Group 2 received 
an identical placebo and a protein supplement. Group 3 received only the protein 
supplement, and Group 4 received nothing, serving as the control. The results indicated 
that Group 1 had significant increases in bench press strength, static strength, and body 
weight compared to Groups 2,3, and 4. It was concluded that 20mg of
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methandrostenolone (a dose higher than the recommended therapeutic dose) can 
effectively accelerate strength and muscle mass gains in experienced weightlifters.
Freed, Banks, Longson, and Burley (1975) tested thirteen male weightlifters, who 
ingested a high protein diet, exercised regularly, and took either 10 or 25 mg/day of 
methandrostenolone or a placebo, in a crossover design, to see what effect it had on 
athletic performance. The athletes chose a low dose (10 mg/day) or a high dose (25 
mg/day) of methandrostenolone and were tested for two consecutive six-week sessions, 
with the anabolic steroid and the placebo given in a random order. The investigators 
insisted on some previous weightlifting experience, and only experienced weightlifters 
were included in the study, this was because when inexperienced participants begin a 
weight training program, the initially rapid strength gains caused by neuromuscular 
adaptations (Hâkkinen, 1994) would theoretically mask any benefits that would occur due 
to anabolic steroid supplementation. Athletic performance was measured as percentages 
of maximum weight lifted in six strength training exercises, including the squat and the 
bench press. Improvements in strength were significantly greater during the anabolic 
steroid supplementation period than during the placebo period. Body weight also was 
measured, and increased significantly during the anabolic steroid period. The weight 
gain was attributed to water retention and not muscle mass. The investigators reasoned 
that anabolic steroids improve athletic performance only when given in combination with 
weight training and a high protein diet. It was theorized that while using anabolic 
steroids, athletes are less susceptible to fatigue, allowing longer, more frequent and 
harder training sessions.
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Win-May and Mya-Tu (1975) conducted a study to assess the effects of anabolic 
steroids on various measures of physical fitness, including anthropometry, balance, 
coordination and flexibility tests, static and dynamic strength, and cardio-respiratory 
endurance. Thirty-one male university students were randomly divided into either the 
anabolic steroid group, who received 5 mg/day of methandrostenolone for three months, 
or the control group, who received a placebo. The results o f this investigation showed a 
significant increase in the anthropometric measurements (body weight, and six body 
circumferences) in the steroid group, compared to the placebo group. Static and dynamic 
strength was also shown to increase in the steroid group. No increases were noted in 
balance, coordination, flexibility or cardio-respiratory endurance with the administration 
o f the anabolic steroid. The investigators also subjectively noted that muscle hypertrophy 
resulted from the administration of the anabolic steroid. It was concluded that anabolic 
steroids have an effect on some areas of physical fimess.
Wynn (1975) cited the powerful effects of anabolic steroids in anorexic patients. 
First, an anorexic girl consumed 3000 calories and a high amount of protein daily for 10 
days. Only a weak positive nitrogen balance was noticed. During the following period, 
when the anabolic steroid methandrostenolone was administered, the positive nitrogen 
balance increased at least threefold, and remained elevated for the 34-day administration 
period. The anabolic steroid period was also associated with a significant weight gain. 
When the anabolic steroid was removed, the positive nitrogen balance ceased and no 
further weight gain was noticed. Another case of the strong effects of anabolic steroids 
involved a teen-age boy who was also anorexic. This time on a 4000 calorie a day diet, 
containing high quantities of protein, a modest positive nitrogen balance was noticed.
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When the anabolic steroid methandrostenolone was administered, the magnitude of the 
positive nitrogen balance increased threefold* and remained elevated for the whole period 
o f anabolic steroid treatment. Again, the positive nitrogen balance associated with the 
anabolic steroid resulted in significant weight gain. When the anabolic steroid treatment 
ceased, the weight gain halted and nitrogen balance returned to zero.
Hervey (1975) and (1976) studied the effects of the anabolic steroid 
methandrostenolone on body composition and muscular strength in untrained men.
Using a crossover, double-blind design, the participants were randomly given the steroid 
(100 mg/day) or a placebo. The two treatment periods (weight training and placebo or 
weight training and steroid administration) were separated by five weeks of abstinence 
from weight training. The results indicated that while on the steroid, the participants 
gained significantly more weight than during the placebo administration period. On the 
basis of total body potassiiun measurements and the significant increase in thigh muscle 
mass width, the weight gained was determined to be in the lean body compartment. The 
increases noticed in muscular strength were not significantly different during either 
steroid or placebo administration. It was concluded that the widely held belief that 
anabolic steroids cause weight gain (lean body mass gain) in young men undergoing 
weight training is true, although, the belief that anabolic steroids improve strength and 
performance was not shown to be true during this study.
Studies with anabolic steroids since 1975 have tended to be more carefully carried 
out, better controlled, and more sophisticated (George, 1988).
Tahmindjis (1976) studied the effects o f self-administration of anabolic steroids in 
twenty male weightlifters. In all participants, body weight was shown to increase.
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ranging from 1.5 to 13.2% of body weight, with an average of a 5.7% increase. Muscle 
strength was also shown to increase dramatically when the participants were using the 
anabolic steroid compared to when they were not. The smallest improvement in 
muscular strength (combination o f bench press and squat strength) noticed while using 
anabolic steroids was 100% greater than the improvement without anabolic steroids; the 
largest improvement was 380%, the average improvement was 195%.
Hervey, Knibbs, Burkinshaw, Morgan, Jones, Chettle, and Vartsky (1981) studied 
the effects o f methandienone on muscular strength and body composition in competitive 
weightlifters. A 100 mg/day dose (a dose sometimes quoted as being as high as some 
athletes take) of the anabolic steroid or an identical placebo were administered for six 
weeks, and then alternated in a double-blind, crossover fashion. During the steroid 
treatment period, body weight, total body potassium and nitrogen, muscle size, and leg 
strength increased dramatically when compared to the placebo period.
Alèn, Hâkkinen and Komi (1984) investigated the changes in body composition, 
muscle fiber characteristics, and isometric and dynamic force output o f the leg extensor 
muscles in five experimental (self-administration of very high doses o f anabolic steroids) 
and six control (no anabolic steroids) power athletes during twenty-four weeks of a 
strength training program. Following the twenty-four weeks o f anabolic steroid self- 
administration, a six-week period without any anabolic steroids followed, and the same 
measurements were taken again. The results indicated that anabolic steroids significantly 
increased body mass (average of 11.25 pounds), lean body mass (average 17 pounds) and 
mean muscle fiber area in the experimental power athletes, while no significant changes 
were noted in any o f the measurements in the control power athletes. Maximum
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isometric force also significantly improved in the experimental group. During the six 
weeks without anabolic steroids, significant changes were noticed in the experimental 
power athletes in body composition and force output. Significant increases were seen in 
dynamic and isometric force, while body mass was significantly decreased. The 
researchers noted that this decrease in body mass could reflect the elimination of fluid 
that was retained during the anabolic steroid period. An interesting point that was noted 
during this study was that during the first six weeks, similar increases in all 
measurements were noticed in both groups. While the study continued, the increases in 
the experimental group far surpassed those of the control group. The researchers 
concluded that the achievements in muscular strength might depend on the duration of 
the steroid use and the training methods utilized.
Alèn and Hâkkinen (1985) performed a case study on an elite bodybuilder who 
self-administered extremely high doses of anabolic steroids over a one year period.
During one twenty-six and one twenty-four week steroid self-administration cycle 
(separated by four weeks without anabolic steroids) total body mass, lean body mass, 
mean fiber area of the vastus lateralis muscle, total thigh girth, and maximum leg 
extension strength all increased significantly. No changes were noticed in maximum 
oxygen uptake or maximum anaerobic power. It was concluded that strength training 
combined with the use of extremely large doses o f anabolic steroids might have increased 
protein synthesis, which resulted in muscle hypertrophy. The authors explained that low 
receptor affinities characterize most of the anabolic steroids so that high doses must be 
administered to obtain anabolic effects greater than those due to a natural training 
stimulus.
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Forbes (1985) analyzed four of his own subjects, along with ten studies that 
measured changes in lean body mass before and after anabolic steroid administration.
His four subjects demonstrated significant increases in lean body mass, and decreases in 
body fat during anabolic steroid administration. It was determined that the magnitude of 
the increases in lean body mass were related to the total amount o f the anabolic steroid 
administered. With low doses o f anabolic steroids, increases in lean body mass were 
only one to two kilograms. When large doses of anabolic steroids were administrated the 
results indicated a progressive increase in lean body mass. Using the available 
information, the author developed a dose-response curve. The x-intercept of the 
regression line for the dose response curve was 2535 mg of total steroid dose; this 
represented the threshold for a significant effect on lean body mass. Forbes (1985) also 
calculated that between the ages of 13 to 20, males have produced 15,330 mg of 
testosterone more than females (6mg/day x 365 days x 7 years). This number represents 
the upper lim it of the dose response curve. The corresponding upper lim it o f lean body 
mass gain was calculated to be 19 kilograms.
Hâkkinen and Alen (1986) investigated the effects of self-administration of 
multiple anabolic steroids and strength training on the physiological performance and 
physical health of an elite bodybuilder. This study was noted as being of great value in 
assessing the effects of anabolic steroids in athletes. It investigated the self­
administration of multiple anabolic steroids, in the dosages often taken by athletes, 
addressing two of the major criticisms of anabolic steroid research. The results of this 
study indicated an extraordinary increase in serum testosterone during anabolic steroid
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supplementation. This rise in testosterone was associated with large gains in fat-free 
mass, mean muscle fiber area, and maximal strength.
Alèn and Hâkkinen (1987) investigated the effects of six months of self­
administered anabolic steroid supplementation on serum hormone levels and maximal 
force development in four top-level Finnish strength athletes (experimental group). Five 
other top-level Finnish strength athletes who did not supplement their training with 
anabolic steroids served as a control group. The investigators commented on the need for 
a study of this design, examining strength development in elite strength athletes who are 
self-administering very high doses of multiple anabolic steroids while involved in heavy 
prolonged weight training. A ll participants were also given a protein supplement. The 
results indicated that total body mass and lean-body mass increased significantly (an 
average of 12 and 22 pounds, respectively) in the experimental group. Muscular strength 
and mean serum testosterone also increased significantly in the experimental group. No 
significant changes were seen in the control group.
Griggs, Kingston, Jozefowicz, Herr, Forbes, and Halliday (1989) investigated the 
effects o f testosterone on muscle mass and protein synthesis in the absence of a weight- 
training program in nine normal male participants. The participants were administered 3 
mg/kg/week of testosterone enanthate for twelve weeks. Muscle mass (estimated by 
creatinine excretion) increased in all nine participants on average 20 %. Muscle protein 
synthesis was also shown to increase on average 27 % in all participants. No significant 
increases in muscle fiber diameter were seen. The investigators concluded that 
testosterone increases muscle mass by increasing muscle protein synthesis.
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Friedel, Dettori, Hannan, Patience, and Plymate (1991) examined the effects of 
supraphysiological doses of anabolic steroids on body composition and muscular 
strength. Thirty male participants were divided into one of four groups who received 
either, (1) 100 mg/week of testosterone enanthate (ser/ed as a replacement dose 
comparison), (2) 300 mg/week testosterone enanthate, (3) 100 mg/week nandrolone 
decanoate, or (4) 300 mg/week nandrolone decanoate, for six weeks. The results 
indicated that body weight significantly increased in groups 2 ,3,and 4, but not group 1. 
No changes were found in skinfold thickness or percent body fat, therefore, the weight 
gained was theorized to be lean body mass. Muscular strength significantly increased in 
all groups except in group 1. The greatest improvements in strength were noticed in 
group 4. Serum testosterone increased threefold in group 2, while no significant increase 
was noted in group 1. The researchers concluded that high doses of anabolic steroids 
(groups 2,3, and 4) produced significant increases in body weight (lean body mass), and 
muscular strength. In group 1, the absence of any changes, and the maintenance of 
normal serum testosterone levels, indicated that 100 mg/week was the same as a 
replacement dose of testosterone.
A study conducted by Forbes, Porta, Herr, and Griggs (1992) looked at the 
changes in body composition caused by testosterone administration. Seven untrained 
subjects were given 3 mg/kg o f intramuscular testosterone enanthate for a total of twelve 
weeks. The participants were told to stick to their normal daily routine (diet and 
exercise). Lean body mass increased progressively throughout the study. The average 
increase in lean body mass was 7.5 kg (range 5.7 -  11.9 kg). The average change in body 
weight was 4.1 kg, thus, on average, 3.4 kg of body fat was lost during the study. The
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participants retained the increased lean body mass for at least five to six months 
following the study, demonstrating that the increases in lean body mass are maintained 
following cessation of the steroid administration. The investigators concluded that the 
changes in body composition were the result of the testosterone supplementation.
Urinary creatinine was measured and indicated that most, if  not all, of the increased lean 
body mass was muscle tissue.
Welle, Jozefowicz, Forbes, and Griggs (1992) investigated the effects of 
testosterone on basal metabolic rate (BMR) and lean body mass in normal men and men 
with muscular dystrophy, for periods lasting three and twelve months. The participants 
were divided into a control (no anabolic steroid) and experimental (testosterone 
injections) group in both the normal men and men with muscular dystrophy. No 
significant changes were demonstrated in either BMR or lean body mass in the control 
groups. The testosterone injections significantly increased plasma testosterone levels for 
the study period (average threefold increase). In normal men, after three months, BMR 
was shown to increase 7%, while men with muscular dystrophy demonstrated a 13% 
increase in BMR; after twelve months, the BMR had still increased a total o f 9% in men 
with muscular dystrophy. Lean body mass (using urinary creatinine excretion) also 
increased significantly (approximately 10.5%) after three months, and remained elevated 
after twelve months. The men with muscular dystrophy who were treated with 
testosterone lost body fat (average 6 kg) during the treatment, while those who received 
the placebo actually gained body fat during the study.
Bhasin, Storer, Berman, Callegari, Clevenger, Phillips, Bunnell, Tricker, Shirazi, 
and Casaburi (1996) looked at the effects of supraphysiologic doses of testosterone on
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muscle size and strength in normal men. The men were randomly assigned to one of four 
groups, a placebo and no exercise group, a placebo and exercise group, a testosterone and 
no exercise group, and a testosterone and exercise group. The participants received either 
600 mg/week of testosterone enanthate or a placebo for 10 weeks. The 600 mg/week 
dose of testosterone enanthate is six times higher than the usual replacement dose 
administered to hypogonadal men. Before and after the treatment, body composition (fat 
free mass) using underwater weighing, muscle size using magnetic resonance imaging, 
and upper and lower body strength using the bench press and squat, respectively, were 
measured. The intake o f energy and protein and the exercise (strength training) program 
were standardized in an attempt to control for some of the factors that have been 
criticized in many of the previous studies conducted on the effects of anabolic steroids on 
performance. Free and total testosterone increased significantly in the two groups who 
received testosterone, but not in either placebo group. The men in the testosterone and no 
exercise group had a significant increase in body weight, coupled with a 3.2 kg average 
increase in lean body mass. The testosterone and exercise group had an average increase 
of 6.1 kg in body weight and an average increase in lean body mass o f 6.1 kg, indicating 
that the weight gained was lean body mass. No significant changes were seen in either of 
the placebo groups for body composition. When muscle size was analyzed, the mean 
cross sectional area o f the arm and leg muscles in the placebo groups did not significantly 
change. Both of the groups that received testosterone had significant increases in cross 
sectional area o f the arm and leg muscles, with the testosterone and exercise group 
greater than the testosterone and no exercise group. The men in the testosterone and no 
exercise group had significant increases in maximum squat and bench press strength of
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19% and 10%, respectively, almost identical to the increases seen in the placebo and 
exercise group. In the testosterone and exercise group, the increases in maximum squat 
and bench press strength were 38% and 22%, respectively, twice as great as the 
testosterone and no exercise and the placebo and exercise groups. The investigators 
concluded that supraphysiological doses of testosterone increase lean body mass, muscle 
size and strength in normal men.
Bhasin, Storer, Berman, Yarasheski, Clevenger, Phillips, Lee, Bunnell, and 
Casaburi (1997) investigated the effects of replacement doses of testosterone on lean 
body tissue and muscle size in hypogonadal males while on a protein and energy 
controlled diet. Participants were given testosterone enanthate (100 mg/week) for 10 
weeks. Body weight increased on average 4.5 kg, with lean body mass increasing 
approximately 5 kg. Cross-sectional area of the triceps and quadriceps, as measured by 
magnetic resonance imaging, both increased significantly. Muscle strength also 
increased approximately 11 kg in the bench press, and 31 kg in the squat, even though the 
participants were not involved in a strength training program. The investigators 
concluded that testosterone replacement in hypogonadal men increases lean body mass 
and muscle size.
Kadi, Erikkson, Holmner, and Thomell (1999) found that the mean area of the 
muscle fibers in high-level power athletes using anabolic steroids were larger than in 
similar athletes who did not use anabolic steroids. The researchers concluded that the use 
of anabolic steroids and strength training cause an increase in the size o f the muscles both 
by hypertrophy and hyperplasia. It was proposed that anabolic steroid use causes the 
activation o f satellite cells, resulting in an increase in the number o f muscle fibers.
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Sattler, Jaque, Schroeder, Olson, Dube, Martinez, Briggs, Horton, and Azen 
(1999) investigated the effects on body weight, lean body mass, muscle cross-sectional 
area, and muscle strength during nandrolone decanoate supplementation, combined with 
weight training in men with human immunodeficiency virus. Participants were divided 
into either a group who received the anabolic steroid (600 mg/day) (A), or a group who 
received the anabolic steroid (600 mg/day) combined with weight training (B). Body 
weight rose on average 4.0 kg and 3.2 kg, and lean body mass (measured by dual energy 
x-ray absorptiometry) increased on average 5.2 kg and 3.9 kg in Group B and A, 
respectively. Muscle cross-sectional area of the thigh, quadriceps and hamstrings, 
measured by magnetic resonance imaging, increased significantly in both groups.
Muscle strength also increased significantly in both groups, with more significant 
increases in Group B.
Taylor, Brooks and Ryan (1999) demonstrated that short-term administration of 
anabolic steroids (nandrolone decanoate) resulted in increased mass and contractile force 
in immobilized and nonimmobilized rabbit skeletal muscle. The authors concluded that 
anabolic steroid administration would result in muscle hypertrophy without weight 
training or a high protein diet.
It has been concluded that in inexperienced weightlifters, neither total and lean 
body mass, muscular strength, nor aerobic strength are likely to be influenced by 
administration o f therapeutic doses of anabolic steroids in the absence o f an exercise 
program that promotes anabolism (Wright, 1980). Even when anabolic steroids are 
administrated during strength training and protein supplementation, strength and body 
weight may not increase more than with training alone (Wright, 1980: Lamb, 1984 and
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1989). For experienced weightlifters, therapeutic doses of anabolic steroids appear to 
enhance the normal increases in body mass that occur with weight training (Wright,
1980; Lamb, 1984 and 1989). The effects on body composition are not as clear as the 
effects on body weight because of factors such as lack of dietary control, different 
anabolic steroids and dosages, different training programs and durations, and individual 
differences in body composition and metabolic rates (Wright, 1980).
Haupt and Rovere (1984) concluded that anabolic steroids w ill consistently show 
increases in muscular strength if  the following criteria are met: 1) anabolic steroids are 
administered to athletes who have trained with weights immediately before 
administration, and who continue weight training during the treatment period; 2) athletes 
maintain a high protein diet; and 3) strength changes are measured by the one repetition 
maximum (IRM) technique for the exercise that the athlete trains.
Studies that Found No Ergogenic Benefits
While most believe that anabolic steroid supplementation increases muscular size 
and strength, and total and lean body mass, not every study has come up with those 
conclusions.
Samuels, Henschel, and Keys (1942) first investigated the effects of anabolic 
steroids on a measure of muscular performance, grip strength. Participants ingested SO 
mg of methyl testosterone daily. No improvements in grip strength, beyond a training 
effect, were noticed in the participants. The authors concluded that no strength 
improvements are obtained with supplementation of SO mg/day o f methyl testosterone.
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The effects of an anabolic steroid (Nibal), either taken alone or in combination 
with exercise (non-weight training workouts), were studied by Fowler, Gardner, and 
Egstrom (1965). Participants were placed into one of four groups, a placebo group, an 
anabolic steroid group, a placebo and exercise group, and an anabolic steroid and 
exercise group. O f interest to the investigators were the effects of the anabolic steroid on 
strength, physical working capacity, a series of anthropometric measurements, and motor 
performance. The results o f this study showed that there were no significant differences 
in any of the measurements between the groups that did not exercise and who received 
either the placebo or the anabolic steroid. The only improvements in performance were 
noted in both exercising groups, with no significant differences between the two groups. 
The investigators concluded that anabolic steroid supplementation in normal doses does 
not increase muscle size or strength, and would be of no use to athletes.
Casner, Early, and Carlson (1971) studied the effects o f an anabolic steroid 
(stanozolol) on body weight, body composition, and muscle strength in normal, 
untrained, young men. Twenty-seven men were placed into one o f four groups; steroid 
and normal daily activity, steroid and weight training, placebo and normal daily activity, 
and placebo and weight training. The participants in the two steroid groups received 2 
mg o f stanozolol three times a day on days 1-21 and 28-49 of the 56-day experiment.
The results indicated no significant increases in muscle strength in any group. An 
increase in body weight was noted for both groups receiving the anabolic steroids, but 
was theorized to be fluid retention. The investigators concluded that anabolic steroids 
cause an increase in body weight, however, the weight gained may have been due to fluid 
retention and not muscle mass and therefore was o f no benefit to athletes.
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In a study conducted by Fahey and Brown (1972), the effects of an anabolic 
steroid (nandrolone decanoate) on strength, body composition, and endurance were 
studied in college aged males with limited weightlifting experience. Participants were 
placed into either the treatment group (1 mg/kg of nandrolone decanoate at week two, 
five, and seven of a nine week program) or the placebo group. While the treatment group 
gained more weight, and increased maximum muscular strength compared to the placebo 
group, none of the differences were statistically significant. It was concluded that the 
anabolic steroid, in the usual recommended dosage, did not enhance strength, lean body 
mass or aerobic capacity. The investigators did acknowledge that the results could have 
been due to the fact that adequate protein intake (protein powder supplementation) seems 
to be necessary for anabolic steroids to be effective.
The effects o f an anabolic steroid on strength development, anthropometric 
measurements, body weight, and aerobic power were investigated by Stremme, Meen, 
and Aakvaag (1974). During the eight-week experiment, twenty-one men were divided 
into a treatment group which received the anabolic steroid at a dosage of 75 mg/day for 
the first four weeks, and 150 mg/day for the last four weeks, or a placebo group. 
Throughout the experiment, all participants were given a protein supplement and 
underwent the same weight training program. The results indicated that for the strength 
development and anthropometric measurements, the steroid group showed gains over the 
control group, but the differences were not statistically significant (the only significant 
increase over the control group was in right thigh circumference). The steroid group 
showed no improvement in aerobic power, and actually showed a slight decrease, while 
the placebo group showed an increase in aerobic power. It was concluded that this
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anabolic steroid (mesterolone) does not improve muscular strength or aerobic power in 
normal healthy men.
Golding, Freydinger, and Fishel (1974) examined the effects of an anabolic 
steroid (methandrostenolone) and a protein supplement on muscle size, strength, and 
body composition in male weightlifters. During a twelve-week study, 40 participants 
were divided into one of four groups, a protein and no steroid group, a steroid and no 
protein group, a steroid and protein group, and a no steroid and no protein group. A ll 
subjects were told that they were taking anabolic steroids and a protein supplement. The 
anabolic steroid groups received 10 mg/day o f methandrostenolone. The type, frequency, 
and intensity of training were not controlled for; all subjects maintained their normal 
training protocol. No significant differences were found between the groups in skeletal 
measurements, body weight, body composition, static strength, or dynamic strength 
measured with the bench press and arm curl. It was concluded that strength athletes 
supplementing their training with 10 mg/day of methandrostenolone, either in the 
presence or absence of additional protein, did not increase body weight, muscular size or 
strength compared to a placebo.
Loughton and Ruhling (1977) investigated the effects of an anabolic steroid 
(methandrostenolone) and protein supplementation on cardiovascular endurance and 
muscular strength while participating in a seven-week endurance and weight training 
program. Twelve males (six trained athletes, and six untrained non-athletes) were 
divided into one of four groups, a trained steroid group, an untrained steroid group, a 
trained placebo group, and an untrained steroid group. The participants in the steroid 
groups received 10 mg of the steroid daily for the first three weeks and 5 mg of the
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steroid daily for the last three weeks; all participants received additional protein 
supplementation. Again, no significant differences were observed in any of the four 
groups for any o f the factors that were measured (strength, oxygen uptake, 
anthropometric measurements) with the exception o f body weight and bench press which 
increased significantly in both steroid groups. The investigators concluded that anabolic 
steroid administration resulted in no significant changes in muscle size or strength, or any 
aerobic adaptations to exercise beyond those found with normal training.
Crist, Stackpole, and Peake (1983) studied the effects of anabolic steroids on 
neuromuscular power and body composition in nine (including one woman) experienced 
weightlifters, receiving protein supplementation. Experienced weightlifters were used in 
this study because novice weightlifters might have gained strength so rapidly from weight 
training alone that any results from anabolic steroid administration may have been 
masked. A ll subjects were randomly assigned to one of three groups and were given the 
three treatments (1 ml of placetx), 100 mg/ml testosterone cypionate, and 100 mg/ml 
nandrolone decanoate) in a double blind, crossover fashion. No significant differences 
were seen in seven o f the ten peak torque measurements obtained from an isokinetic 
dynamometer. Mean lean body mass and body fat were also unaffected by administration 
of either anabolic steroid. The investigators concluded that anabolic steroids do not 
produce any signiflcant changes in body composition or neuromuscular power. The 
investigators theorized that the dosage or duration o f steroid administration might have 
been inadequate to produce any significant improvements in the performance 
measurements o f this study.
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While the difficulty in assessing anabolic steroid research has already been 
discussed, Haupt and Rovere (1984) explain that the studies that did not show a 
significant increase in muscle strength usually had some similarities including 1) the use 
o f inexperienced weightlifters; 2) the use o f anabolic steroids other than 
methandrostenolone; and 3) the use of strength testing techniques other than one 
repetition maximums (IRM) for weight lifting exercises.
Controversy as to the effects of anabolic steroids on performance has persisted 
since the 1970’s, primarily because of misinformation from the medical and scientific 
communities. From anecdotal evidence and self-administration, athletes had concluded 
that anabolic steroids increased muscular size and strength, and thus improved 
performance. The medical and scientific communities reached much the opposite 
conclusion. Brown and Tait (1973) stated that in order to discourage steroid use, a 
number of physicians and sports scientists resorted to the same scare tactics that proved 
so ineffective in curbing the use of recreational drugs. Taylor (1987) concluded that by 
failing to distinguish between the effects o f anabolic steroids on trained and untrained 
subjects, the scientific community came to faulty conclusions in the mid-1970 s. The 
conclusions resulted in the publication of official position statements that anabolic steroid 
use did not enhance athletic performance, and a halt in research on the effects of anabolic 
steroids on athletes (Taylor, 1987).
The original American College of Sports Medicine (1977) position statement on 
the use of anabolic steroids stated that administration to young, healthy people (below 
age SO) in medically approved therapeutic doses, does not bring about any significant 
improvements in strength, endurance, lean body mass, or body weight. Any positive
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effects come about because the users have been led to expect some positive effects 
(placebo effect). Also, the report stated that there is no conclusive evidence that 
extremely large doses of anabolic steroids aid or hinder athletic performance. The 
position statement concluded that because of the failure of studies to show improvements 
in muscular strength, lean body mass, or body weight after therapeutic doses of anabolic 
steroids, it is obvious that any benefits are likely to be small and not worth the health 
risks (American College o f Sports Medicine, 1977).
The medical community's unconditional stance on anabolic steroids cost them 
their credibility and alienated athletes (Wright, 1980; Taylor, 1987). Some excellent 
examples came from (Ward, 1972) where Alan Ryan, the team physician at the 
University o f Wisconsin and a former president o f the American College of Sports 
Medicine, stated that the use of anabolic steroids is a complete waste of time and money, 
and Daniel Hanley, the official doctor to the United States Olympic team, emphasized 
that steroids have no effect on muscle strength. Athletes continued to believe that 
anabolic steroids improved performance, and therefore used them even though the 
medical community denied their role in improving performance (Taylor, 1987; Blue & 
Lombardo, 1999; Taylor et al., 1999).
Anabolic Steroid and Endurance 
Because anabolic steroids are used medicinally to stimulate erythropoiesis 
(Wilson & Griffin, 1980; Lombardo, 1993) and treat certain anemias (Lamb, 1989), 
supplementation in athletes could theoretically increase the oxygen carrying capacity of 
blood, thus increasing maximal oxygen uptake (VO2 max) (Lombardo, 1993). Wilson
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(1988) indicated that part o f the weight gain noticed while using anabolic steroids may be 
increased blood volume and hematocrit.
O’Shea (1970) studied the effects of anabolic steroid administration in swimmers. 
The intent o f the study was to determine the influence, if  any, of anabolic steroids during 
an activity that demands cardiovascular endurance and speed. Oxygen uptake, static 
strength and maximum performance (speed) were measured before and after steroid 
supplementation in fifteen college male swimmers. Eleven participants were divided into 
either Group A (who received 10 mg of methandrostenolone (anabolic steroid) for the 
first three weeks, followed by three weeks of placebo) or Group B (who received the 
placebo for the first three weeks followed by three weeks of methandrostenolone). Four 
participants served as controls in Group C. The results indicated that anabolic steroid 
administration had no effect on static strength, speed, or oxygen uptake. The author 
noted that all subjects in this study had very high levels of cardiovascular fitness, and 
statistically significant improvements in this group of people would be very difficult. It 
was concluded that anabolic steroid treatment alone (in the absence of a high protein diet) 
is ineffective in improving athletic performance.
Johnson, Roundy, Allsen, Fisher, and Silvester (1975) studied the effects of 
anabolic steroids on endurance training exclusively. The investigators stated that 
previous studies which showed no relationship between anabolic steroid supplementation 
and changes in endurance performance involved strength training exclusively. Maximum 
oxygen uptake (VOzmax), mile-run time, and body composition (skinfold thickness) 
were measured in subjects who administered an anabolic steroid (or a placebo) and a 
protein powder, and who participated in a supervised running program over a three-week
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period. The results o f the study showed no significant differences between the group 
supplemented with anabolic steroids, and the placebo group. Thus, the investigators 
concluded that anabolic steroids do not appear to have any positive effects on endurance 
exercise performance or body composition (percent body fat).
Looking at the results of other studies, utilizing strength training exclusively, only 
two had demonstrated an increase in maximum oxygen uptake (Johnson & O’Shea, 1969; 
Ward, 1970) while many others demonstrated either no ergogenic benefit (Bowers & 
Reardon, 1972; Fahey & Brown, 1973; Hervey et al., 1976; Johnson et al., 1972; Johnson 
et al., 1975; Win-May & Mya-Tu, 1975), or a significant decrease in aerobic performance 
(Stromme et al., 1974) following anabolic steroid administration.
In reviewing all current literature. Lamb (1989) and Haupt and Rovere (1984) 
concluded that there is no scientific support to justify anabolic steroids as ergogenic aids 
for improving aerobic performance over what regular aerobic training would do. 
Lombardo (1993) explained that, instead, endurance athletes might administer anabolic 
steroids in an attempt to improve recovery time, allowing more frequent, longer, and 
higher intensity workouts.
Summary of Anabolic Steroid Research 
The American College of Sports Medicine Position Stand on the Use of Anabolic- 
Androgenic Steroids in Sports (1987) concluded that 1) anabolic steroids in the presence 
of an adequate diet can contribute to increases in body weight, often in the lean mass 
compartment; 2) the gains in muscular strength achieved through high-intensity exercise 
and proper diet can be increased by the use of anabolic steroids in some individuals; and.
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3) anabolic steroids do not increase aerobic power or capacity for muscular endurance. 
Lombardo, (1993) concluded that based on the available scientific evidence and the 
overwhelmingly consistent anecdotal reports of athletes, anabolic steroids w ill increase 
strength and lean body mass in subjects -  especially experienced weight lifters -  who 
perform high-intensity exercises and consume adequate diets.
To date, no controlled studies of the effects of anabolic steroids as ergogenic aids 
have been performed on females (MacDougall, 1983; Lombardo, 1993). It is theorized 
that even greater increases in muscle mass and strength may be noticed in females using 
anabolic steroids compared to males because of the lower circulating level of testosterone 
in females (MacDougall, 1983; George, 1988; Lombardo, 1993).
Possible Mechanism of Action 
While there is general agreement that anabolic steroid use enhances performance 
by increasing muscular size and strength, the exact mechanism for this is unclear. 
Possible mechanisms include 1) an increase in protein synthesis; 2) inhibition of the 
catabolic effects of glucocorticoids (anticatabolic effects); 3) effects on the central 
nervous system (CNS); and, 4) the placebo effect (American College of Sports Medicine, 
1987; Lombardo, 1993).
Increased Protein Synthesis 
Testosterone (and anabolic steroids) is lipid soluble and readily diffuses into the 
cell (George, 1988). Rogozkin (1979) demonstrated the existence o f androgen receptors 
in skeletal muscle treated with anabolic steroids. Anabolic steroids combine with an
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androgen receptor in the cytoplasm in skeletal and cardiac muscles, the prostate gland, 
skin, and various areas of the brain (Wright, 1980; Lamb, 1984; Wilson, 1988;
Lombardo, 1993). The hormone receptor complex interacts with receptor sites within the 
chromosomes to promote the transcription of genes, and the synthesis of messenger RNA 
molecules (Wright, 1980; Lamb, 1984; Wilson, 1988; Lombardo, 1993). The increased 
RNA synthesis translates into the synthesis of more protein in the ribosomes o f the cells 
(Wright, 1980; Lamb, 1984; Lombardo, 1993). Rogozkin (1979), Hough (1990), and 
Blue and Lombardo (1999) suggest that anabolic steroids increase skeletal muscle actin 
and myosin protein synthesis. Hough (1990) states that strength training without 
anabolic steroids increases the number of steroid receptor sites in muscle, while strength 
training combined with anabolic steroids not only causes an increase in the number of 
receptor sites but also saturates them.
In some tissues, testosterone is first metabolized to estradiol and 5a- 
dihydrotestosterone via the aromatase and 5a reductase enzymes, respectively, in order to 
be effective (George, 1988; Bardin et al., 1991). Estradiol and 5a-dihydrotestosterone 
act via the estrogen and androgen receptors, respectively (Bardin et al., 1991). Casaburi 
et al. (1996) and Wilson (1988) explain that in healthy men, the androgen receptors in 
most tissues are fully saturated or might even be down regulated by the androgen levels. 
Thus, if  androgens are to be effective in healthy men, a mechanism other than the 
androgen receptor must be involved, presumably with a dose-response relationship 
(Bardin et al., 1991). Since the receptors are not entirely specific, some of the effects of 
supraphysiological doses of anabolic steroids are mediated via estrogen and progestin 
receptors (Bardin et al., 1991).
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Anticatabolic Effects 
Anabolic steroids have their most pronounced effects in athletes who are in a 
chronic catabolic state caused by training (Haupt & Rovere, 1984). It has been 
hypothesized that the anabolic response in muscle could be due to a blocking of 
catabolism induced by glucocorticoids binding to their receptors, slowing protein 
breakdown (Wright, 1980; Haupt & Rovere, 1984; Mellion, 1984; Blue & Lombardo, 
1999). Anabolic steroids competitively inhibit and displace glucocorticoids (Wright, 
1980). Anabolic steroids can convert a negative nitrogen balance to a positive one, given 
adequate protein intake (Haupt & Rovere, 1984; Lamb 1989). Wilson (1988) stated that 
at supraphysiological doses, anabolic steroids act as glucocorticoid antagonists and 
promote a positive nitrogen balance independent of the androgen receptor.
Boone, Lambert, Flynn, Michaud, Rodriguez Zayas, and Andres, (1990) 
demonstrated that anabolic steroid users had significantly lower increases in creatine 
kinase concentration, and a faster clearance rate following identical strength training 
programs when compared to a control group who did not use anabolic steroids. This 
indicates a decrease in skeletal muscle damage following exercise. Cortisol 
concentration significantly increased following the strength training program in the 
control group, while no significant increase was observed in the anabolic steroid group, 
indicating possible suppression of glucocorticoids. The researchers concluded that 
anabolic steroid users have a diminished creatine kinase response and an altered stress 
response to a bout of exercise.
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Effects on the CNS
Another theory on how anabolic steroid work deals with the androgenic (CNS) 
action of the drugs (Brooks, 1983; Lamb, 1989; Lombardo, 1993). It has been theorized 
that anabolic steroids make athletes more aggressive and competitive, allowing them to 
train harder, for a longer period of time, and to recover quicker from workouts. Thus, the 
increases in performance are a result o f more intense and a greater volume of training. 
Hervey (1975) stated that if  steroids are taken during training, fatigue is halted and that 
the extra work performed during each training session provides the real ergogenic 
benefits. Taylor (1987) stated that while taking anabolic steroids, athletes experience a 
euphoric state with diminished fatigue, allowing them to train more intensely. Some 
athletes take anabolic steroids in the hope that they w ill decrease healing time after a 
muscle injury like a pull or a strain (Mellion, 1984). Although these authors (Hervey, 
1975; Brooks, 1983; Taylor, 1987) have theorized that anabolic steroids work solely 
through the CNS, Lamb (1989) has stated that the only evidence to support this theory 
consists o f subjective sensations of greater strength gains in athletes undergoing steroid 
treatment compared to a placebo.
The Placebo Effect
The placebo effect (psychological mechanisms) has been suggested as a possible 
mechanism o f action for anabolic steroids by some authors (Ryan, 1981; Lombardo, 
1993). Ariel and Seville (1972) demonstrated the psychological (placebo) effect of 
anabolic steroid supplementation in fifteen varsity male athletes undergoing weight 
training. Four months prior to the actual study, the participants exercised with weights
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five days a week. A ll participants were told of the benefits and dangers o f anabolic 
steroid use, and that some would receive the anabolic steroids during the study while 
others would not. Six participants were given what they were told were anabolic steroids, 
but were actually placebos. The results of the study indicated that the strength gains 
measured in four weight training exercises were greater during the placebo 
(experimental) period than during the pre-placebo period. The experimenters concluded 
that taking the placebo supplied the psychological benefits needed to enhance strength 
gains above and beyond what would be expected. This study demonstrated the powerful 
psychological effect that cannot be excluded from any ergogenic aid research. In 
contrast, Wilson (1988) suggested that if  this were a significant phenomenon, one would 
expect the effects on muscle strength to be more consistent in the double blind studies of 
athletic performance, when actually the results are inconsistent. In reality, athletes do 
not care whether the improvements in muscular strength are caused by the anabolic 
effects of steroids on muscle mass or psychologically induced improvements, as long as 
there are improvements (Lamb, 1989).
Other Mechanisms
Another possible mechanism for the effects of anabolic steroid usage is related to 
the increased secretion of other anabolic hormones. Anabolic steroids may also stimulate 
growth hormone secretion in adults (Alèn & Rahkila, 1988). Hough (1990) noted that 
during anabolic steroid administration, growth hormone secretion is between S and 60 
times greater than baseline measurements.
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Alèn et al. (1984), Hâkkinen and Alen (1986), and Bardin et al. (1991) have 
suggested that anabolic steroids may only be effective in large doses. Because relatively 
low receptor affinities characterize most of the anabolic steroids, high doses of these 
drugs should be administered in order to obtain any anabolic effects greater than those 
due to the natural training stimulus (Alèn et al., 1984; Hâkkinen & Alen, 1986). The 
effects of anabolic steroids may be uniform, but o f a small magnitude so that they are 
statistically difficult to demonstrate (Bardin et al., 1991). However, even small effects 
could be a benefit to a top athlete. As the caliber of the athlete increases, the effects on 
athletic performance become more difficult to assess (Wilson, 1988). The effects may 
be related to the log of the dose, and benefits on performance may be observed at 10 or 
more times the replacement dose for hypogonadal men (Bardin et al., 1991). Studies 
showing the maximal effects of androgens in animals are only observed at 
supraphysiological doses support this hypothesis (Bardin et al., 1991).
Bardin et al. (1991) have hypothesized that there is genetic polymorphism 
among individuals. Only a small subset w ill show a large response to the administration 
of anabolic steroids. Studies in inbred mice show that some strains have as much as a 20- 
fold greater response to anabolic steroids than others (Bardin et al., 1991). Hough (1990) 
has stated that individual differences in the responses to anabolic steroids are well known.
Steroid Alternatives
In 1990, the federal government passed the Anabolic Steroid Control Act (Yesalis 
& Wright, 1993), listing anabolic steroids as Schedule III controlled substances. With the 
passage o f this law, the Drug Enforcement Agency (DEA) controls the manufacture.
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importation, distribution and dispensing o f anabolic steroids (Yesalis & Wright, 1993). 
Possession of anabolic steroids without a legitimate prescription is now a criminal 
offense. When this law went into effect, some athletes and bodybuilders were unable to 
find a source to supply them with anabolic steroids. Many athletes turned to dietary 
supplements with hopes that their use would produce results similar to anabolic steroid 
administration.
Dehydroepiandrosterone 
While many different supplements have been marketed to athletes as steroid 
alternatives, the most popular have been "testosterone precursors” , such as 
dehydroepiandrosterone (DHEA) and androstenedione. Testosterone precursors are 
administered with the belief that their use w ill increase endogenous testosterone 
production in the body, and therefore, produce effects similar to those seen when 
anabolic steroids are administered (McArdle et al., 1999). The use of testosterone 
precursors has increased in popularity since 1996 when they were first sold as dietary 
supplements in the USA (Brooks et al., 2000). DHEA was the first testosterone precursor 
marketed to athletes. Brown et al. (1999c), Wallace et al. (1999), and Welle, Jozefowicz, 
and Statt (1990) determined that supplementation with DHEA does not increase serum 
testosterone or protein metabolism. Thus, DHEA was not found to be an effective 
alternative to anabolic steroid usage. Recently, androstenedione was marketed as the 
newest version of testosterone precursor purported to increase serum testosterone 
concentrations and act like anabolic steroids in the body.
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Androstenedione and Androstenediol 
Androstenedione (Figure 2) is a steroid hormone produced endogenously in the 
gonads and adrenal glands of all humans (Leder et al., 2000). The production of 
androstenedione is approximately 3.4 mg per day in females and 1.4 mg per day in males 
(Horton & Tait, 1966). Androstenedione is synthesized from dehydroepiandrosterone 
and can be converted into testosterone via the enzyme 17 p-hydroxysteroid 
dehydrogenase (Leder et al., 2000). Androstenedione serves as the immediate precursor 
to testosterone in the endogenous production of testosterone (Wallace et al., 1999). 
Androstenedione is characterized as a weak androgen in humans, with only minimal 
amounts being converted into testosterone in males (Wallace et al., 1999). In males, a 
greater amount is converted into estrogen hormones (Wallace et al., 1999). In females, as 
much as 60% of their testosterone may come from the peripheral conversion of 
androstenedione to testosterone (Horton & Tait, 1966). Androstenedione also serves as 
an immediate precursor to the hormone estrone (E l), which can then be converted into 
the more metabolically active estrogen, estradiol (E2) (Longcope, Kato & Horton, 1969). 
This conversion of androgens to estrogens takes place to a greater extent in males when 
compared to females (Longcope et al., 1969). While previous studies (Longcope et al., 
1969; Edman, C.D., Aiman, E.J., Porter, J.C., & MacDonald, P.C., 1978; Kley,
Deselaers, Peerenboom, & Kniskemper, 1980) have found that adipose tissue contains 
the enzyme aromatase, which aromatizes androgens to estrogens, Matsumine, Hirato, 
Yanaihara, Tamada, & Yoshida (1986) found that skeletal muscle in both males and 
females can also convert androgens into estrogens. Edman et al. (1978) stated that the 
skin and the brain can also aromatize androgens into estrogens. This peripheral
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aromatization o f androgens (including androstenedione) is the main source of estrogens 
in males, and represents a substantial amount of the estrone produced in females 
(Longcope et al., 1969). In males (Thomson, Wallace, & Cook, 1989) and females 
(Diagnostic Products Corporation, 1999a), androstenedione exhibits a diurnal variation, 
where it is highest in the morning; it also has cyclical variation during the female 
menstrual cycle, where it is highest near the middle of the cycle (Diagnostic Products 
Corporation, 1999).
ANDR.OSTENEDIONE
Figure 2: Androstenedione Chemical Structure
Androstenediol (Figure 3) is another steroid hormone that can be converted to 
testosterone in the body. According to Ballantyne et al. (2000), androstenediol can also 
be synthesized from dehydroepiandrosterone and converted into testosterone via the 
action of the enzyme 3 p-hydroxysteroid dehydrogenase (Earnest et al., 2000). The most 
common pathway for the synthesis o f testosterone involves the degradation of
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pregnenolone to 17a-hydroxypregnenolone, to dehydroepiandrosterone, to 
androstenediol, and finally to testosterone (Ballantyne et al., 2000). Testosterone can 
also be synthesized by another pathway involving the conversion of pregnenolone to 
progesterone and the subsequent formation of 17-hydroxypregnenolone and 
androstenedione, which can be converted to estrone (then to estradiol) or testosterone 
(Ballantyne et al., 1999).
OH
ANDROSTENEDIOL
Figure 3; Androstenediol Chemical Structure
Androstenedione and Androstenediol Studies 
Early studies with androstenedione and other testosterone precursors (including 
androstenediol) were completely unrelated to their possible use as ergogenic aids. 
Instead, the early studies were conducted in an attempt to determine if  weaker androgens 
could be converted into more potent ones. In general, the results indicated that human 
blood does contain the enzymes necessary to convert weaker androgens (like
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androstenedione) into stronger ones (like testosterone) (Mahesh & Greenblatt, 1962; 
Horton & Tait, 1966; Blaquier, Forchielli, & Dorfman, 1967).
Mahesh and Greenblatt (1962) found that orally administered 
dehydroepiandrosterone and androstenedione could be converted into testosterone in 
females. Dehydroepiandrosterone ingestion resulted in a 3-4-fold increase in plasma 
testosterone, while androstenedione ingestion caused a 4-7-fold increase in plasma 
testosterone.
Horton and Tait (1966) found that in females, a significant amount of testosterone 
is derived from androstenedione (as high as 60% peripheral conversion of 
androstenedione to testosterone). In males, plasma androstenedione conversion to 
testosterone is less than 0.3%. A negligible amount of plasma testosterone comes from 
androstenedione in males. One of the major findings of this study was that only 1.8% of 
orally administered androstenedione and 5.9% of intravenous androstenedione enters the 
plasma as testosterone.
Blaquier et al. (1967) demonstrated that androgen transformation and 
interconversions could take place in human blood. Small amounts of 
dehydroepiandrosterone were converted to androstenedione and testosterone. Larger 
amounts of androstenedione were converted to testosterone, but the androgen that was 
most readily (highest percentage) converted into testosterone was androstenediol. The 
researchers concluded that human blood can convert less active androgens into more 
biologically active ones.
The first reported use of androstenedione as an ergogenic aid came firom East 
Germany, where athletes began administering it as early as 1981 (Franke & Berendonk,
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1997). The androstenedione was not taken orally; instead, it was administered via a nasal 
spray (Franke & Berendonk, 1997).
Other than the original early studies performed on testosterone precursors, no data 
was available to assess the possible ergogenic benefits o f their use. As a result, a number 
of studies have recently been performed to test whether these dietary supplements 
increase serum concentrations o f testosterone and muscle size and strength (Ballantyne et 
al., 1999; Brown et al., 1999a; Brown et al., 1999b; King et al., 1999a; King et al., 1999b; 
Parsons et al., 1999; Quindry et al., 1999; Reifenrath et al., 1999; Wallace et al., 1999; 
Earnest et al., 2000; Leder et al., 2000; Rasmussen et al., 2000). To date almost all 
studies have investigated the orally administered versions of the testosterone precursor 
dietary supplements, with androstenedione being the most often used.
The results o f the majority o f the studies indicate that orally administered 
testosterone precursors do not increase serum testosterone concentrations or muscle size 
and strength (Ballantyne et al., 1999; Brown et al., 1999a; Brown et al., 1999b; King et 
al., 1999a; King et al., 1999b; Parsons et al., 1999; Quindry et al., 1999; Reifenrath et al., 
1999; Wallace et al., 1999; Rasmussen et al., 2000). Wallace et al. (1999) explained that 
the bioavailability o f oral testosterone precursors is only approximately 5%, due to the 
effects of digestion, liver metabolism, and tissue enzyme activity. Horton and Tait 
(1966) found that 89% of orally administered androstenedione is converted to 
testosterone glucuronide and excreted in the urine.
Wallace et al. (1999) conducted a study to compare the effects o f short-term 
dehydroepiandrosterone (DHEA) versus androstenedione supplementation on body 
composition, muscular strength, and hormonal levels in middle-aged male weightlifters.
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Participants were randomly divided into groups who received either 100 mg/day of a 
placebo, androstenedione, or dehydroepiandrosterone. No significant changes were 
observed in any measure of muscular strength (bench press or leg press), body 
composition (total body mass, lean body mass, or fat mass) or hormonal levels 
(testosterone or androstenedione). These results indicated that supplementation with 
either androstenedione or dehydroepiandrosterone did not increase lean body mass or 
muscular strength levels compared to the placebo.
Quindry et al. (1999) administered either 200 mg/day o f a placebo, 
androstenedione, or androstenediol to 50 middle-aged men in combination with heavy 
resistance weight training, for a 12-week period. Both the androstenedione and 
androstenediol groups demonstrated increases in serum androstenedione of 183% and 
62%, respectively. At one- and two- month periods, the androstenedione group 
demonstrated a significant increase in total testosterone, which returned to normal by the 
end of the treatment period. No changes in serum testosterone levels were found in the 
androstenediol group. Estrogen concentrations were significantly increased in the 
androstenedione group at each measurement (1,2, and 3 months). The androstenediol 
group only had significantly increased estrogens at the end of the treatment period (3 
months). The investigators concluded that the main effects of oral androstenedione or 
androstenediol administration in middle-aged men are significant increases in estrogen- 
related hormones and a down-regulation in testosterone synthesis within one month of 
continuous androstenedione use.
The acute (Parsons et al., 1999) and long-term (Brown et al., 1999b), (King et al., 
1999a), (Reifenrath et al., 1999) effects o f an anabolic supplement, AN6 (containing
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androstenedione), have been investigated in college-aged males. Participants received 
either a placebo, DHEA, or AN6. The results of acute administration indicated that 
serum androstenedione was increased following the intake of DHEA and AN6. Neither 
serum testosterone nor estradiol were increased following acute administration of AN6 
(Parsons et al., 1999). In the long-term studies, serum testosterone and estradiol 
concentrations (King et al., 1999a), body composition and muscle strength (Reifenrath et 
al., 1999), and glucose tolerance, insulin action and blood lipids (Brown et al., 1999b) 
were examined in a group of college-aged males undergoing 8 weeks o f resistance 
training supplemented with either a placebo, DHEA, or AN6. Serum testosterone was 
unaffected by any supplement. Serum estradiol and estrone levels were elevated with 
AN6 supplementation. The investigators concluded that AN6 does not increase serum 
testosterone, but increased androgen conversion to estrogens. AN6 also did not enhance 
changes in muscle strength or body composition during strength training. The AN6 
supplement was shown to reduce serum HDL cholesterol, increasing the risk for coronary 
artery disease. In addition, insulin sensitivity was not increased with strength training 
during AN6 supplementation.
Brown et al. (1999a) investigated the effects of placebo, androstenedione (300 
mg/day), or androstenediol (300 mg/day), combined with herbal extracts, on serum sex 
steroid levels in middle-aged men. Serum testosterone was unchanged in any group; 
serum androstenedione and estradiol were significantly elevated in the androstenedione 
and androstenediol groups. The researchers concluded that androstenedione and 
androstenediol do not increase serum testosterone levels.
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King et al. (1999b) investigated the acute and long-term effects o f oral 
androstenedione supplementation in combination with a weight training program. Thirty 
healthy young men volunteered for the study. First, the short term effects of 
androstenedione supplementation were investigated in ten participants in a crossover, 
double-blind fashion. The participants received either 100 mg of androstenedione or a 
placebo. Blood samples were drawn every 30 minutes for six hours and analyzed for the 
androstenedione and for free and total testosterone concentrations. The results indicated 
that ingestion of androstenedione increased the serum androstenedione concentration up 
to 325-350 %. However, serum concentrations of free and total testosterone were 
unaffected. The effects of androstenedione during strength training were investigated in 
the other 20 participants, who were randomly assigned into a group who received either 
300 mg of androstenedione (treatment group) or a placebo (control group) daily for 6 of 
the 8 weeks of the weight training program. The serum androstenedione concentration 
was significantly elevated in the treatment group. Even though serum free testosterone 
concentrations were significantly higher in the treatment group before and following the 
treatment, the androstenedione supplementation did not significantly alter free 
testosterone concentrations in either group. Total testosterone was also unaffected in 
either group following treatment. Serum estradiol and estrone concentrations were 
significantly elevated in the treatment group after supplementation and when compared to 
the control group. Weight training caused a significant increase in muscle strength in 
both groups, with no significant differences between the two groups. Mean cross- 
sectional area of the type II muscle fibers increased similarly in both groups. The 
investigators concluded that supplementation with androstenedione, both long- and short­
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term, did not significantly alter serum testosterone concentrations, muscle size, or muscle 
strength in healthy young males. Serum estradiol and estrone concentrations were 
significantly elevated following androstenedione supplementation, indicating 
aromatization of androstenedione or o f testosterone, possibly derived from the exogenous 
androstenedione supplementation.
Ballantyne et al. (1999) investigated the effects of androstenedione 
supplementation in healthy young males during normal activity and while undergoing 
weight training. First, participants ingested 200 mg of androstenedione daily for 2 days; 
blood samples were drawn every three hours for twelve hours on the second day and 
twenty-four hours after ingestion of the last p ill on the third day o f the experiment. At 
least two weeks later, the same subjects, in a crossover design, were administered either 
androstenedione or a placebo at a dosage o f200 mg per day for two days. Blood samples 
were drawn just before, immediately after, and 90 minutes after a weight training 
workout. The results demonstrated that androstenedione supplementation elevated serum 
androstenedione levels 2-3-fold. There were no significant differences in testosterone 
levels at any time of the day during the supplementation periods. While estradiol 
concentrations were higher during supplementation, the differences were not statistically 
significant. Following exercise, free and total testosterone levels were elevated during 
both conditions, with no significant differences as a result o f androstenedione 
supplementation. Serum estradiol concentrations were also elevated following exercise, 
and remained significantly elevated for at least 90 minutes after exercise with 
androstenedione supplementation. During both conditions, serum testosterone was well 
within the normal range and displayed a normal circadian rhythm. The researchers
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concluded that androstenedione supplementation had no effect on plasma testosterone 
during a twenty-four hour period. The researchers also concluded that exercise interacted 
with androstenedione supplementation to exaggerate the conversion of androstenedione 
to estradiol. According to this study, androstenedione supplementation appears to be of 
no benefit to the male athlete.
Rasmussen et al. (2000) investigated the effects of five days of oral 
androstenedione supplementation (100 mg/day) on muscle protein synthesis and serum 
hormone levels. The results indicated that plasma androstenedione concentrations 
increased three-fold, causing a significant increase in serum estradiol concentrations. 
Plasma testosterone levels did not change during the investigation. An increase in muscle 
protein breakdown was noticed during androstenedione supplementation. Muscle protein 
synthesis was also slightly elevated during the supplementation, but the change was not 
different from the control condition, nor was it as large as the increased muscle protein 
breakdown. In other words, the net protein balance was negative during androstenedione 
supplementation, indicating protein catabolism. This trend towards increased protein 
breakdown was theorized to have been a consequence of the increased estradiol levels. 
The authors concluded that oral androstenedione supplementation did not stimulate 
muscle protein anabolism or increase serum testosterone levels. Instead, it was theorized 
that oral androstenedione was aromatized to estradiol and probably reduced and 
conjugated for excretion by the liver. Previous studies have shown that 89% of orally 
administered androstenedione was converted to testosterone glucuronide and excreted in 
the urine (Horton & Tait, 1966). Androstenedione was shown to have no direct anabolic 
effects on muscle.
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Only two published studies indicated that testosterone precursor dietary 
supplements do increase serum testosterone concentrations, and therefore might contain 
ergogenic effects (Earnest et al., 2000; Leder et al., 2000).
Earnest et al. (2000) set out to determine if  androgenic hormone precursors for 
testosterone could be transformed into testosterone. Eight male participants were treated 
in a crossover fashion with either 200 mg o f androstenedione, androstenediol, or a 
placebo. Blood sample were drawn every 30 minutes for 90 minutes. Analysis of the 
data revealed that the mean area under the curve (AUC) for serum androstenedione was 
greater during androstenedione administration than during androstenediol or placebo 
administration. During androstenedione administration, a significant increase in free and 
total testosterone was demonstrated when compared to the placebo group, but not the 
androstenediol group. The investigators concluded that androstenedione, and possibly 
androstenediol, when taken orally, can increase testosterone concentrations in healthy 
young men.
Leder et al. (2000) investigated the effects of oral androstenedione administration 
on serum androstenedione, estradiol, estrone, and testosterone levels in healthy young 
men. Participants were randomly divided into groups that received either 100 mg/day or 
300 mg/day o f androstenedione, or placebo (0 mg/day) for seven days. The results 
indicated that the mean changes in AUC for serum testosterone in the groups receiving 0, 
100, and 300 mg/day of androstenedione were -2%, -4%, and 34%, respectively. The 
change in the 300 mg/day group was significant compared to the placebo and 100 mg/day 
groups. In the 100 mg/day group, the mean AUC for androstenedione, estrone, and 
estradiol increased 72%, 74%, and 42%» respectively. In the 300 mg/day group, the
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mean AUC for androstenedione, estrone, and estradiol increased 697%, 196%, and 128%, 
respectively. Mean daily baseline serum testosterone and estrone concentrations did not 
change, while mean daily serum androstenedione and estradiol increased significantly 
over the seven day period in the 300 mg/day group. In the 100 mg/day group, no subjects 
had serum testosterone concentrations that exceeded the upper lim it o f normal, but 4 of 
14 subjects in the 300 mg/day group had levels that exceeded the upper lim it of normal. 
Twelve o f IS and 10 o f 14 participants in the 100 mg/day and 300 mg/day groups, 
respectively, had estradiol levels above the upper lim it of normal for males. The 
investigators concluded that higher doses of orally administered androstenedione can 
increase serum testosterone and estrogen levels.
Even though Blaquier et al. (1967) found that androstenediol is more readily 
converted into testosterone than any other androgen precursor, few studies (Brown et al., 
1999a; Quindry et al., 1999; Earnest et al., 2000) have investigated the possible ergogenic 
effects of this substance. Two of the studies. Brown et al. (1999a) and Quindry et al. 
(1999), concluded that androstenediol does not increase serum testosterone 
concentrations, and therefore is not effective as an ergogenic aid. Earnest et al. (2000) 
concluded that androstenediol possibly has ergogenic effects.
Only one study published to date has investigated an alternate delivery method 
(transdermal) o f a testosterone precursor, androstenedione (Stoppe & Krause, 1986). 
Stoppe and Krause (1986) administered percutaneous (transdermal) testosterone, 
androstenedione (1.25 mg/m^body surface area), and estradiol to the skin of healthy 
young men to investigate the effects on serum steroid hormone levels. Testosterone and 
estradiol administration led to short peaks in their respective serum concentrations.
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Androstenedione did not alter the serum levels of any of the hormones measured. It was 
concluded that precursor steroids, including androstenedione, are rapidly metabolized to 
other compounds before they could reach the blood in any sizable amount.
While most studies have investigated whether androgen precursor supplements 
can raise serum testosterone levels, one study looked at the urinary metabolites of 
androgen precursor supplementation, and whether ingestion of these products could lead 
to a positive drug test for anabolic steroids. Uralets and Gillette (1999) investigated the 
excretion products of the orally administered androgen precursors androstenedione, 
androstenediol, and norandrostenedione. After oral administration of androstenedione, 
all participants had significantly higher concentrations of androsterone and 
etiocholanolone in their urine. Androsterone and etiocholanolone are two of the major 
urinary metabolites of testosterone (Schânzer, 1996). Urinary testosterone and 
epitestosterone concentrations also rose briefly, with testosterone rising faster than 
epitestosterone. This rapid rise in testosterone, coupled with the fact that most men 
respond to androstenedione administration with a greater rise in urinary testosterone (T) 
relative to epitestosterone (E), could cause the T/E ratio to rise over 6, which would result 
in a positive drug test for the use of anabolic steroids. The urinary metabolites 
disappeared in less than 24 hours. The researchers explained that it is uncertain whether 
the ingestion o f androstenedione would cause an increase in serum testosterone, because 
androstenedione, like other anabolic steroids has a high rate of metabolic inactivation 
when administered orally. Androstenediol administration caused an increase in urinary 
testosterone ten times greater than that o f androstenedione. Epitestosterone also rose to 
levels greater than were seen during androstenedione administration; thus the T/E ratio
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was not as high as in androstenedione administration. The urinary metabolites 
disappeared after 20 hours. The main excretion products of norandrostenedione are 
norandrosterone and noretiocholanolone, the same metabolites as the anabolic steroid 
nandrolone (nortestosterone), because norandrostenedione is rapidly converted to 
nortestosterone. The concentrations of the major metabolites in the first urine samples 
were as high as 100,000 ng/ml, higher than seen with the injectable (parenteral) anabolic 
steroid nandrolone. Other than the unusually high first urine output, the urinary 
metabolites of norandrostenedione are identical to those of nandrolone. Norandrosterone 
and noretiocholanolone are detectable in a urine sample up to 10 days after a single SO 
mg dose. This study indicated that supplementation with androstenedione and 
norandrostenedione could cause the user to fail a drug test for anabolic steroids.
When all o f the available data on androstenedione administration in males is 
analyzed, most studies have concluded that orally administered androstenedione is not 
converted to testosterone; it is instead aromatized into estrone, which can then be 
converted into estradiol. Therefore, androstenedione and the other popular testosterone 
precursors have no performance enhancing actions in males.
To date, no studies have assessed the possible ergogenic benefits o f 
androstenedione supplementation in females. Mahesh & Greenblatt (1962) found that 
ingestion of androstenedione did increase testosterone levels for a short time. Horton & 
Tait (1966) found that as much as 60% of the testosterone in females may come from the 
peripheral conversion of androstenedione to testosterone. It is theorized that, because 
females have a much lower circulating level o f testosterone when compared to males.
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increasing the level o f testosterone could lead to greater increases in muscle mass and 
strength (MacDougall, 1983; George, 1988; Lombardo, 1993).
In summary, while exogenous testosterone administration has been shown to 
increase serum testosterone levels, thus improving athletic performance by increasing 
muscle size and strength, it has been concluded that the administration of testosterone 
precursors, including androstenedione and androstenediol, does not increase serum 
testosterone levels in males. A ll but one of the studies have looked at orally administered 
androstenedione. To date, no studies have investigated the possible ergogenic effects of 
testosterone precursor supplementation in females, or the effects of the administration of 
a transdermal testosterone precursor containing androstenedione and androstenediol. 
Therefore, the purpose o f my study is to examine the acute effects o f transdermal 
androstenedione and androstenediol administration (the dietary supplement 
AndrosteDERM®) on the serum steroid hormone levels of androstenedione and free and 
total testosterone in females.
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CHAPTERS
METHODOLOGY
Subjects
Seven healthy college-aged females volunteered to participate in this study. The 
participants were selected on the basis of being in general good health, not being 
pregnant, and no previous history of anabolic steroid, testosterone, or testosterone 
precursor supplementation. The average age (and standard deviation) of the participants 
was: 23.43 ± 4.31 years. Participants signed an informed consent (Appendix I) prior to 
participation. The UNLV Institutional Review Board approved the use o f human 
subjects for this study (Appendix I).
AndrosteDERM®
AndrosteDERM® is a transdermal testosterone precursor cream produced by 
Medlean (Duxbury, MA). It contains the testosterone precursors androstenedione and 
androstenediol, and is sold without a prescription at a number o f health food retailers as a 
dietary supplement. The recommended daily dosage of 2 ml is supposed to contain 130 
mgs o f a mixture of androstenedione and androstenediol. The cream is to be applied once 
daily to any number of locations including the inner upper arm, the inner thigh, and the 
back.
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In order to assure purity, a 10 ml sample of AndrosteDERM® was sent to 
Integrated Biomolecule Corporation (Tucson, AZ) for a HPLC purity assay. The results 
of the assay (Appendix II) indicated that I ml o f AndrosteDERM® contained 21.8 ± 0.26 
mg of androstenedione and 44.6 ± 0.37 mg of androstenediol. These results are in 
agreement with the manufacturers claim that 2 ml o f AndrosteDERM® contained, in 
total, 130 mg o f a mixture of androstenedione and androstenediol.
Test Protocol
A ll testing was conducted in the morning, beginning between 8am and 12pm, to 
account for the normal diurnal variation in androstenedione levels (Diagnostic Products 
Corporation, 1999). Subjects were advised to go about their normal daily schedules on 
the day of testing; the subjects need not be fasted, and no other special preparations are 
necessary for proper analysis (Diagnostic Products Corporation, 1999).
Using aseptic technique, a registered nurse drew an approximately 6 ml baseline 
sample of blood from an antecubital vein. One ml of the AndrosteDERM® cream was 
applied to the inner surface of the left upper arm. Every 45 minutes for the next six hours 
following the initial application o f the AndrosteDERM®, another approximately 6 ml 
sample of blood was drawn. A total of nine samples of blood, totaling approximately 54 
mis, were drawn.
Blood Analysis
The collected blood samples were centrifuged at 700 xg for 12 minutes the same 
day; the plasma was removed and frozen at -  80 °C until analysis. Serum
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androstenedione and free and total testosterone concentrations were analyzed using 
radioimmunoassay (Diagnostic Products Inc., Los Angeles, CA) by an independent 
laboratory. An independent laboratory was chosen do perform the radioimmunoassay 
procedures because the University of Nevada, Las Vegas lacks the equipment and 
experienced personal.
Design
The study was a 1 (Subject) X 9 (Time) within-subjects design. The factor time 
had nine levels; 0 minutes (baseline), 45 minutes, 90 minutes, 135 minutes, 180 minutes, 
225 minutes, 270 minutes, 315 minutes, and 360 minutes post treatment. The dependent 
variables of interest were serum androstenedione, free testosterone, and total testosterone 
concentration.
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RESULTS AND DISCUSSION 
Serum Androstenedione Concentration 
When the serum androstenedione values calculated from the radioimmunoassay 
procedure were assessed, a number of the values were beyond the expected physiological 
level for females (Diagnostic Products Corporation, 1999a) (Table I). A ll data from 
Table 1 appears in Figure 4. However, values such as 44.47 ng/ml, 17.03 ng/ml and 
57.70 ng/ml are beyond the expected range for females (males as well) (Diagnostic 
Products Corporation, 1999a). Subjects who had at least one value that was beyond the 
expected range of 0.4 to 2.7 ng/ml (Diagnostic Products Corporation, 1999a) were 
excluded, leaving one subject. Subject I (Table 2). This made statistical analysis 
impractical.
Table I: Androstenedione Raw Data For A ll Subiects tin ng/ml)
Omin 4Smin 90min 135 min 180 min 225 min 270 min 315 min 360 min
Subject 1 1.68 1.66 1.92 2.03 1.85 1.61 1.26 1.26 1.39
Subject 2 3.33 28.83 2.73 2.60 2.40 2.44 2.55 2.74 2.19
S u t ^ 3 44.47 7.76 8.23 7.82 9.28 4.52 7.73 8.84 9.49
Subject 4 4.05 4.00 7.16 4.77 8.85 4.63 7.52 17.03 3.99
Subject 5 19.16 6.98 6.11 5.75 5.33 5.91 6.14 8.25 6.72
Subject 6 4.41 23.39 3.60 3.56 3.02 3.97 3.75 4.77 4.14
Subject 7 7.60 2.80 2.61 2.40 2.88 5.62 4.62 57.70 3.23
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Figure 4; Serum Androstenedione Versus Time Plot For A ll Subjects
Table 2: Androstenedione Values fin ng/ml) (Exclusion of Unexpected Values)*
Omin 4 5 min 9 0 min 135min 180min 225min270min 315min 360min 
Subject 1 1.68 1.66 1.92 2.03 1.85 1.61 1.26 1.26 1.39
* Values that were beyond the expected values range (Diagnostic Products Corporation, 
1999a) were excluded which resulted in 6 of the 7 subjects being excluded
The data from Subject I (Table 2) appears in Figure S. The serum 
androstenedione concentration for Subject I appeared to rise slightly from 45 minutes 
post application to 225 minutes post application. It then fell below baseline for the rest of 
the testing period. This could be due to absorption of the AndrosteDERM® or the
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normal diurnal androstenedione variation for females (Diagnostic Products Corporation, 
1999a).
Subject 1 Androstenedione
s- 2.5
0.5
90 135 180 225 270 315 3600 45
Time (min)
Figure 5: Serum Androstenedione Versus Time Plot For Subject 1
Serum Free Testosterone Concentration 
When the serum free testosterone values calculated from the radioimmunoassay 
procedure were assessed, a number of the values were beyond the expected physiological 
level for females (Diagnostic Products Corporation, 1999b) (Table 3). A ll data from 
Table 3 appears in Figure 6. However, values such as 202.88 pg/ml, 63.82 pg/ml and 
69.88 pg/ml are beyond the expected range for females (Diagnostic Products 
Corporation, 1999b). Subjects who had at least one value that was beyond the expected 
range of 0.06 to 2.57 pg/ml (Diagnostic Products Corporation, 1999b) were excluded, 
leaving one subject. Subject 1 (Table 4). This made statistical analysis impractical.
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Table 3: Free Testosterone Raw Data For A ll Subiects (in pg/mO
Omin 4 5 min 9 0 min 135min 180min 225min270min 315min360min
Subject 1 2.15 0.94 1.01 0.87 1.28 1.08 1.30 1.95 1.77
Subject 2 1.47 5.85 1.43 1.49 1.33 1.89 1.92 3.34 1.86
Subject 3 202.88 26.16 34.49 24.89 43.60 9.24 36.59 39.13 45.13
Subject 4 6.12 14.96 26.64 17.33 63.82 6.35 20.64 12.35 7.42
Subject 5 22.09 17.56 13.62 5.06 6.69 7.58 17.63 13.75 6.82
Subject 6 6.53 69.88 4.28 3.19 3.88 5.87 3.93 6.23 6.24
Subject 7 9.88 2.70 1.79 2.12 3.38 8.10 8.23 89.92 9.06
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Figure 6: Serum Free Testosterone Versus Time Plot For A ll Subjects
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Table 4: Free Testosterone Values fin pg/mll (Exclusion of Unexpected Values)*
Omin 4 5 min 9 0 min 135min 180min 225min 270min 315min 360min 
Subject 1 2.15 0.94 1.01 0.87 1.28 1.08 1.30 1.95 1.77
* Values that were beyond the expected values range (Diagnostic Products Corporation, 
1999b) were excluded, which resulted in 6 of the 7 subjects being excluded
The data from Subject 1 (Table 4) appears in Figure 7. The serum free 
testosterone concentration for Subject 1 declined sharply from application to 45 minutes 
post application. It then began to rise, reaching near baseline concentration at 315 
minutes post application.
Subject 1 Free Testosterone
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I
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90 135 180 225 270 315 3600 45
Time (min)
Figure 7: Serum Free Testosterone Versus Time Plot For Subject 1
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Serum Total Testosterone Concentration 
When the serum total testosterone values calculated from the radioimmunoassay 
procedure were assessed, a number of the values were beyond the expected physiological 
level for females (Diagnostic Products Corporation, 1999c) (Table 5). A ll data from 
Table 5 appears in Figure 8. However, values such as 3290.03 ng/dl, 225.42 ng/dl and 
130.06 ng/dl are beyond the expected range for females (Diagnostic Products 
Corporation, 1999c). Subjects who had at least one value that was beyond the expected 
range of 0 to 81 ng/dl (Diagnostic Products Corporation, 1999c) were excluded, leaving 
two subjects. Subjects 1 and 2 (Table 6). This made statistical analysis impractical.
Table 5: Total Testosterone Raw Data For A ll Subjects (in ne/dl)
Omin 4 5 min 9 0 min 135min 180min 225min270min 315min360min 
Subject 1 24.11 10.65 19.88 16.81 20.57 16.24 14.41 32.50 20.12
Subject 2 29.88 75.48 30.78 36.86 33.59 38.27 45.26 56.17 57.79
Subject 3 3290.03 49.16 93.68 89.18 240.25 84.63 195.96 240.36 256.29
Subject 4 46.90 52.06 132.91 79.05 225.42 50.40 104.98 53.25 84.51
Subject 5 72.80 651.05 64.27 41.07 50.79 52.49 96.00 93.05 65.97
Subject 6 62.77 333.09 47.37 53.59 69.78 97.31 93.39 130.06 151.39
Subject 7 103.71 32.26 31.09 37.72 54.45 86.72 97.35 868.62 51.29
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Total Testosterone
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Figure 8: Serum Total Testosterone Versus Time Plot For A ll Subjects
Table 6; Total Testosterone Values (in ng/dl) (Exclusion of Unexpected Values)*
Omin 4 5 min 9 0 min 135min 180min 225min270min 315min360min 
Subject 1 24.11 10.65 19.88 16.81 20.57 16.24 14.41 32.50 20.12
Subject 2 29.88 75.48 30.78 36.86 33.59 38.27 45.26 56.17 57.79
* Values that were beyond the expected values range (Diagnostic Products Corporation, 
1999c) were excluded which resulted in 5 of the 7 subjects being excluded
The data from Subjects 1 and 2 (Table 6) appears in Figure 9. The serum total 
testosterone concentration for Subject 1 declined sharply from baseline to 45 minutes 
post application. The general trend for the rest of the testing period was to rise, reaching 
a peak level at 315 minutes post application. For Subject 2, the total testosterone 
concentration rose sharply from baseline to 45 minutes post application. It then declined 
to approximately baseline levels at 90 minutes post application. From 90 minutes post
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application, the general trend for Subject 2 was a steady increase in total testosterone, 
reaching a peak concentration at 360 minutes post application. Whether serum total 
testosterone levels continued to rise after that point is unknown. This increase in total 
testosterone could be caused by the peripheral conversion of androstenedione or 
androstenediol supplied via AndrosteDERM®.
Subject 1 and 2 Total Testosterone
80.00
60.00
% % 40.00
20.00
0.00
Time (min)
Subject 1 -e-Subject 2
Figure 9: Serum Total Testosterone Versus Time Plot for Subjects I and 2
While serum androstenedione, free and total testosterone levels were analyzed 
using radioimmunoassay, much of the data received (including baseline levels) was 
beyond the physiological levels possible for females, indicating a methodological error. 
Therefore, the data for most of the subjects had to be eliminated from statistical analysis. 
While the general trend did not indicate a rise in serum androstenedione, free or total 
testosterone following application, too few subjects remained following elimination to 
run the appropriate statistical analysis.
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CHAPTERS
SUMMARY AND RECOMMENDATIONS 
Summary
Testosterone is an anabolic hormone; it promotes the building of new tissue, such 
as skeletal muscle, by increasing protein synthesis (anabolic action) and decreasing 
protein breakdown (anticatabolic action) (Blue & Lombardo, 1999). The serum 
concentration of testosterone in males is ten times that o f females (Gard, 1998), which 
Wynn (1975) states is responsible for the greater amount of muscle mass seen in males.
Anabolic steroids are synthetic versions of the hormone testosterone. Because 
anabolic steroids have powerful tissue building effects, it is believed that their use w ill 
cause the accretion o f skeletal muscle mass and strength, although, the exact mechanism 
at work remains unknown.
With the scheduling of anabolic steroids as controlled substances in 1990 (Yesalis 
& Wright, 1993), the possession o f anabolic steroids without a legitimate medical 
prescription became a criminal ofifense. Many athletes and bodybuilders turned to legal 
dietary supplements in hopes that their use would produce effects similar to those o f 
anabolic steroids. Some of the most popular dietary supplements purported to have 
“muscle building”  effects similar to anabolic steroids are testosterone precursors (or 
prohormones), with androstenedione and androstenediol being two of the most popular. 
In the human body, both androstenedione and androstenediol serve as immediate
75
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precursors to the hormone testosterone (Wallace et al., 1999; Earnest et al., 2000). 
Androstenedione can be converted to testosterone via the hormone 17 P-hydroxysteroid 
dehydrogenase (Leder et al., 2000). Androstenediol can be converted into testosterone 
via the enzyme 3p-hydroxysteroid dehydrogenase (Earnest et al., 2000). Thus, it is 
theorized that if  these testosterone precursor supplements are administered, they w ill be 
converted into testosterone, increasing the serum testosterone concentration. It is 
believed that by increasing the endogenous production o f testosterone in the body, results 
similar to those seen during anabolic steroid administration (increased muscle mass and 
strength) w ill be recognized.
Recently, a number of studies (Ballantyne et al., 1999; Brown et al., 1999a;
Brown et al., 1999b; King et al., 1999a; King et al., 1999b; Parsons et al., 1999; Quindry 
et al., 1999; Reifenrath et al., 1999; Wallace et al., 1999; Earnest et al., 2000; Leder et al., 
2000; Rasmussen et al., 2000) bave been conducted on males to determine if  the use of 
oral testosterone precursors, including androstenedione and androstenediol, w ill increase 
serum testosterone levels, and produce anabolic effect seen while using anabolic steroids. 
The results o f the majority o f the studies indicate that orally administered testosterone 
precursors do not increase serum testosterone concentrations or muscle size and strength 
(Ballantyne et al., 1999; Brown et al., 1999a; Brown et al., 1999b; King et al., 1999a; 
King et al., 1999b; Parsons et al., 1999; Quindry et al., 1999; Reifenrath et al., 1999; 
Wallace et al., 1999; Rasmussen et al., 2000). Only two published studies indicated that 
supplementation with testosterone precursor dietary supplements does increase serum 
testosterone concentrations, and therefore, may have ergogenic value (Earnest et al., 
2000; Leder et al., 2000).
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It has been detennined that the bioavailability o f oral testosterone precursors is 
only approximately 5%, due to the effects of digestion, liver metabolism, and tissue 
enzyme activity (Wallace et al., 1999). Thus, alternate methods for testosterone 
precursor delivery have been developed in an attempt to increase their bioavailability. 
Transdermal and sublingual versions of androstenedione and androstenediol have been 
marketed with claims stating better results than those seen with oral testosterone 
precursors.
Only one study published to date has investigated an alternate delivery method 
(transdermal) o f a testosterone precursor, androstenedione (Stoppe & Krause, 1986). 
Stoppe and Krause (1986) administered percutaneous (transdermal) testosterone, 
androstenedione (1.25 mg/m^body surface area), and estradiol to healthy young men in 
order to investigate the effects on serum steroid hormone levels. Testosterone and 
estradiol administration led to short peaks in their respective serum concentrations. 
Androstenedione did not alter the serum levels of any o f the hormones measured, 
including androstenedione and testosterone. It was concluded that precursor steroids, 
including androstenedione, are rapidly metabolized to other compounds before they can 
reach the blood in any sizable amount. In the case o f androstenedione, it would be 
metabolized in the liver to such products as androsterone, etiocholanone, 5a- and 5p- 
androstandiols (Uralets & Gillette, 1999), and testosterone glucuronide (Horton & Tait, 
1966) to be excreted in the urine.
To date, no studies have ever been conducted on females to determine whether 
testosterone precursor administration may behold ergogenic benefits. I f  testosterone 
precursor dietary supplements do increase serum testosterone levels, and thus hold
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ergogenic benefits, females should exhibit a greater response to their administration 
because of much lower serum testosterone concentrations and the fact that as much as 
60% of testosterone in females comes for the peripheral conversion of androstenedione 
(Horton & Tait, 1966).
Mahesh and Greenblatt (1962) found that orally administered 
dehydroepiandrosterone and androstenedione could be converted into testosterone in 
females. Ingestion of 100 mgs o f androstenedione caused a 4-7-fold increase in plasma 
testosterone. The researchers concluded that androstenedione could be converted into 
testosterone in the human body. The present study was designed to determine whether 
the acute administration of a transdermal testosterone precursor supplement in females 
(AndrosteDERM®) would elevate serum androstenedione and free and total testosterone 
levels above baseline over the six hour testing period.
In the present study, the data obtained as a result of the radioimmunoassays may 
not be correct, making the results obtained questionable. While all blood collection was 
performed properly, an error appeared to have occurred somewhere between sampling 
and the final results. Some of the subsequent data obtained was not physiologically 
possible for men or women. Proper interpretation of the data is unwarranted without 
retesting all o f the blood samples. Conclusions and generalizations cannot be made at 
this time.
Recommendations
Based on the current study, the following recommendations are offered for future 
research:
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1. Conduct the study with a larger number of subjects. For monetary reasons,
this study could only use seven subjects, and because of apparent errors that 
occurred somewhere after the blood collection, a number of the subjects had 
to be eliminated from statistical analysis because of unexpected values. This 
left either one or two subjects depending on the dependant variable. An 
increase in the number of subjects could potentially offset a similar problem in 
a similar study.
2. Conduct each sample in duplicate (or triplicate) during the radioimmunoassay 
procedure. Errors occurred somewhere after collection of the blood samples. 
If the errors were in the radioimmunoassay, performing duplicate (or 
triplicate) analyses on each sample could potentially document that error.
3. Increase the testing period beyond six hours. More blood sample could have
been collected 12, and possibly 24, hours post application in order to test for a 
sustained increase in androstenedione, free or total testosterone.
4. Either in males or females, a shidy with a longer duration could be conducted. 
Instead of the acute effects of a one time application of AndrosteDERM®, the 
effects of application of AndrosteDERM® for one week or longer could 
determine whether continued usage w ill elevate androstenedione, free or total 
testosterone levels, and if  the increase is sustained for a period of time.
5. Analyze other metabolites or hormones. A urine analysis could detect 
metabolites that may cause a failed drug test for anabolic steroids. Analyzing 
serum estrogen levels (estrone and estradiol) could determine if  the 
androstenedione is being converted into testosterone or estrogen hormones.
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DATE: March 28,2001
TO: Mark Rasmussen
Kinesiology 
M/S 3034
FROM: ^  Dr. Carl Reiber
UNLV Biomedical Sciences Institutional Review Boardf
RE: Status of Human Subject Protocol Entitled:
“The Acute Effects of AndrosteDERM Administration on Serum Steroid Levels 
and Grip Strength”
OPRS# S04s0800-062
This memorandum is official notification that the UNLV Biomedical Sciences Institutional 
Review Board approved the protocol for the project listed above and work on the project may 
proceed. This approval is effective March 27,2001 and will continue for a period of one year.
Should the use of human subjects described in this protocol continue beyond a year from the 
approval date, it will be necessary to request an extension.
If  you have any questions or require any assistance, please contact the Office for the Protection of 
Research Subjects at 895-2794.
cc: OPRS File
Office for the Protection of Research Subjects 
4505 Maryland Parkway •  Box 451046 •  Las Vegas. Nevada 89154-1046 
(7021895-2794 •  FAX (702) 895-4242
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University of Nevada Las Vegas 
Informed Consent Statement
THE ACUTE EFFECTS OF TRANSDERMAL TESTOSTERONE 
PRECURSOR ADMINISTRATION ON SERUM STEROID 
HORMONE LEVELS IN FEMALES
Information
You are invited to participate in a research study investigating the acute effects of 
a transdermal testosterone precursor supplement, AndrosteDERM®, on the serum 
steroid hormone levels o f androstenedione and free and total testosterone.
Procedures
You w ill be asked to report to the Sports Injury Research Center for one six-hour 
testing session.
As listed on the packaging, AndrosteDERM® is an all-natural, non-prescription, 
nutritional product (this product is labeled as a dietary supplement by the FDA, 
not a food or a drug) that can be purchased at health food stores. It is a 
transdermal (absorbed through the skin) version of the testosterone precursors 
androstenedione and androstenediol, used for performance enhancement in sports 
requiring power.
Dietary supplements are regulated under a different set o f regulations than those 
covering foods and drugs (over-the-counter and prescription). Under the Dietary 
Supplement Health and Education Act o f 1994 (DSHEA), the manufacturer of the 
dietary supplement is responsible for ensuring that it is safe before it is marketed. 
The FDA is then responsible for taking action against any unsafe dietary 
supplement after it reaches the market, not before. In most cases, the 
manufacturers of dietary supplements do not need to register with the FDA or get 
FDA approval before producing or selling their products.
The procedures of the study w ill be explained to you upon your arrival to the 
Sports Injury Research Center. At this time, you w ill be asked to sign the 
informed consent and participation in the study w ill begin. Using aseptic 
technique, a registered nurse w ill draw a baseline blood sample (approximately 6 
ml) from an antecubital vein (front o f the elbow). One (I) ml (21.8 mg of 
androstenedione and 44.6 mg of androstenediol, a total o f 66.4 mg) of 
AndrosteDERM® w ill be applied to the inner surface o f your left upper arm. 
Blood samples of 6-ml each w ill be drawn every 45 minutes for six hours from 
the initial application o f AndrosteDERM®. The total amount o f blood drawn w ill 
be approximately 54 mis.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
83
THE ACUTE EFFECTS OF TRANSDERMAL TESTOSTERONE
PRECURSOR ADMINISTRATION ON SERUM STEROID
HORMONE LEVELS IN FEMALES
Benefits of Participation
1. Satisfaction from participating in a research project and contributing to the 
body of human performance literature.
2. An increased understanding of the acute effects o f testosterone precursor 
supplementation on serum steroid hormone levels.
Risks
In this experiment, the risk to the participant is minimal. A registered nurse w ill 
perform all o f the blood draws using aseptic technique. There is always a risk of 
infection when a blood sample is drawn. The risk is minimized with the use of 
disinfectants, gloves, aseptic technique, and sterile equipment. There is the risk of 
bruising associated with any venipuncture. Bruising usually resolves in 7-10 
days. This risk is minimized by using correct technique for blood drawing.
Sterile, one time use, disposable needles w ill be used. Universal blood and body 
fluid precautions w ill be carried out at all times. Used needles w ill be disposed 
immediately after use in a sharps container. The risk o f skin 
redness or irritation following the application of the topical cream is also possible. 
The possible effects are mitigated with the one-time application of a low dosage 
of AndrosteDERM®.
The researcher and a registered nurse w ill be monitoring you during the study. If 
you feel any discomfort during the study, notify the researcher or the registered 
nurse and the study w ill be stopped immediately. If  any other problems should 
arise, the researcher w ill address the situation.
There are no known risks associated with the acute administration of a 
testosterone precursor. Most studies conducted on testosterone precursors have 
been performed on males, with no side effects being reported with their acute 
(one-time) use. With chronic use (eight weeks), a lowering o f HDL cholesterol 
was reported, although, the serum concentration did not reach a level that is 
considered a risk factor for cardiovascular disease (King et al., 1999). No negative 
side effects were reported in males who received either 100 or 300 mg of 
androstenedione daily for seven days (short-term); the authors indicated that long­
term use could be hazardous, particularly in women and children (Leder et al., 
2000).
Some potential side effects associated with the chronic use of testosterone 
precursors in males include elevated estrogen levels, which may cause 
gynecomastia or other feminizing effects, and may increase the risk for 
cardiovascular disease, and prostate and pancreatic cancer (King et al., 1999). In
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women, the chronic use of testosterone precursors could elevate serum 
testosterone levels, possibly causing hirsutism or virilization (Leder et al., 2000).
In the only known study on testosterone precursor administration in females, the 
female participants ingested lOOmg of androstenedione (Mahesh and Greenblatt, 
1962). Peak testosterone levels were noticed 60 minutes after administration and 
had begun declining 90 minutes following administration (Mahesh and 
Greenblatt, 1962). No side effects were reported with the one-time administration 
o f the androstenedione, or the transient rise in testosterone (Mahesh and 
Greenblatt, 1962). In the only known study ever to investigate the transdermal 
administration o f a testosterone precursor, when the androstenedione was 
administered to the male participants, no rise in serum androstenedione, 
testosterone, or estradiol was reported (Stoppe and Krause, 1986).
The potential for side effects associated with the use of testosterone precursors in 
females is mitigated by the one-time (acute, not chronic) administration of a low 
dose (66.4 mg) of the testosterone precursor.
The effects o f an acute (one-time) dose o f AndrosteDERM® on the menstrual 
cycle are unknown. Because serum testosterone levels may be elevated with the 
application o f AndrosteDERM®, the date when menses occurs may be effected; it 
may be either earlier or later than expected. Again, the effects on the menstrual 
cycle are unknown.
Confct
If  you have any questions at any time about the study, or if  you experience 
adverse effects as a result of participation in this study, you may contact the 
researchers; Mark Rasmussen at 895-2780 or Dr. John Young at 895-4626. For 
questions about your rights
as a research participant, you may contact the UNLV Office for the Protection of 
Research Subjects at 895-2794.
Participation
Your participation in this study is voluntary. You may refuse to participate in this 
study or in any part o f this study. At any time you may withdraw without 
prejudice to your relations with UNLV or the director o f this study. I f  you 
withdraw, you should understand that your data would be destroyed. You may ask 
any questions about this study prior to its beginning or at any time during the 
investigation.
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ConfidentuUitv
No reference w ill be made in written or oral materials that could link you to this 
study A ll data w ill be placed in a locked cabinet in the Sports Injury Research 
Center at UNLV.
Copwnt
I have read and understand the above information. My questions have been 
answered by the director of the study. I agree to participate in this study.
Subject s Signature Date
Researcher’s Signature Date
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QUESTIONNAIRE
Participant Initials (first, middle, last) 
Participant Number (leave blank)
SECTION 1; General Information
1. Name:
2. Age:
SECTION 2: Medical History
1. Because androgen levels could change during this study, it would be inappropriate to 
include any women who are, or might be pregnant. Are you, or is there any chance 
that you might be pregnant?
2. The use o f anabolic steroids and/or testosterone precursors (including 
androstenedione) can cause changes in the androgen levels in the body, which would 
confound the results of this study. Are you currently using, or have you ever used 
anabolic steroids and/or testosterone precursors?
3. The use o f certain medications, over-the-counter medicines, or dietary supplements 
could interfere with the results of this study. Are you currently taking any? I f  yes, 
please list.
4. The use o f healthy subjects is necessary for this study; certain disorders could 
interfere with the results. Have you ever been diagnosed or hospitalized with a 
chronic disease? I f  yes, please explain.
S. Certain allergies could potentially compromise your participation in this study. Do 
you have any allergies? I f  yes, please list the substances you are allergic to and the 
type of reaction to the substance.
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Human Subjects Protocol
THE ACUTE EFFECTS OF TRANSDERMAL TESTOSTERONE
PRECURSOR ADMINISTRATION ON SERUM STEROID
HORMONE LEVELS IN FEMALES
Name; Mark Rasmussen & Dr. John Young 
Department; Kinesiology
Title o f Study; The Acute Effects of Transdermal Testosterone Precursor Administration 
on Serum Steroid Hormone Levels in Females
1 SUBJECTS;
Ten healthy UNLV female students w ill be recruited for participation in this study. An 
informed consent form and questionnaire (see attached forms) w ill be used to alert the 
test investigator o f any conditions that may affect participation in the study. The 
questionnaire w ill be administered to the participants to survey medical history and any 
past or present ergogenic aid use.
2. PURPOSE. METHODS. AND PROCEDURES;
Purpose
The purpose o f this study is to examine whether administration of the over-the-counter 
dietary supplement and testosterone precursor, AndrosteDERM®, w ill affect the steroid 
hormones androstenedione and testosterone (free and total). Research has shown that the 
compounds androstenedione and androstenediol are precursors to the hormone 
testosterone in the body. AndrosteDERM® contains the testosterone precursors 
androstenedione and androstenediol. Dietary supplement companies recently marketed 
these and similar compounds as ergogenic aids that are supposed to increase serum 
testosterone levels in the body, thus producing the benefits of higher testosterone in the 
body, including increased muscle strength and muscle hypertrophy. To date, research on 
testosterone precursor supplementation has been performed on oral versions in males, and 
has had mixed results. A new and supposedly superior version of testosterone precursors, 
transdermal (as in the supplement AndrosteDERM®), has been developed and is on the 
market. To date, no research has been performed on AndrosteDERM®. Evaluation of 
the effects o f a new form of supplement delivery (transdermal) may provide clear 
answers as to whether or not testosterone precursor supplements raise serum testosterone 
levels and thus, may enhance physical performance.
Procedures
Each participant w ill report to the Sports Injury Research Center for one six-hour testing 
session. Prior to testing, each participant w ill be asked to complete an informed consent 
form and an information questionnaire (see attached forms). Participants w ill be 
informed o f the specific protocol o f the study, but w ill remain naïve as to the theoretical
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question. Following the introduction, specific instructions w ill be given prior to the start 
of testing.
Using aseptic technique, a registered nurse w ill draw a baseline blood sample 
(approximately 6-ml) from an antecubital vein (front o f the elbow). Next, 1 ml of 
AndrosteDERM® w ill be applied to the inner surface of the left upper arm. Every 45 
minutes for the next six hours, another 6-ml sample of blood w ill be drawn via 
venipuncture. The total number of venipunctures w ill be 9; the total amount of blood 
drawn w ill be approximately 54 mis.
3. RISKS:
For the proposed experiment the risk to the participant is minimal. A registered nurse 
w ill draw all blood samples (using aseptic technique), and be present throughout the 
entire testing period. The participant w ill also be allowed to stop testing at any time, for 
any reason. There is always the risk o f bruising when blood samples are drawn. This 
risk is minimized by using correct technique for blood drawing. There is a risk of 
infection when blood samples are drawn. The risk is minimized with the use of 
disinfectants, aseptic technique, sterile equipment, and latex gloves. Sterile, one time 
use, disposable needles w ill be used. Universal blood and body fluid precautions w ill be 
carried out at all times. Used needles w ill be disposed immediately after use in a sharps 
container. The risk o f skin redness or irritation following the application o f the topical 
cream is also possible. The possible effects are mitigated with the one-time application 
of a low dosage o f AndrosteDERM®.
Because this is a one-time single dose of AndrosteDERM®, the potential risks associated 
with testosterone precursor use are minimal. AndrosteDERM® is a testosterone 
precursor that contains androstenedione and androstenediol, natural products found in all 
humans. It is labeled as a dietary supplement and is available over-the-counter at health 
food stores. It does not require a doctor’s prescription.
There are no known risks associated with the acute administration of a testosterone 
precursor. Most studies conducted on testosterone precursors have been performed on 
males, with no side effects being reported with their acute (one-time) use. With chronic 
use (eight weeks), a lowering o f HDL cholesterol was reported, although, the serum 
concentration did not reach a level that is considered a risk factor for cardiovascular 
disease (King et al., 1999). No negative side effects were reported in males who received 
either 100 or 300 mg o f androstenedione daily for seven days (short-term); the authors 
indicated that long-term use could be hazardous, particularly in women and children 
(Leder et al., 2000).
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Some potential side effects associated with the chronic use of testosterone precursors in 
males include elevated estrogen levels, which may cause gynecomastia or other 
feminizing effects, and may increase the risk for cardiovascular disease, and prostate and 
pancreatic cancer (King et al ., 1999). In women, the chronic use of testosterone 
precursors could elevate serum testosterone levels, possibly causing hirsutism or 
virilization (Leder et al., 2000).
In the only known study on testosterone precursor administration in females, the female 
participants ingested lOOmg of androstenedione (Mahesh and Greenblatt, 1962). Peak 
testosterone levels were noticed 60 minutes after administration and had begun declining 
90 minutes following administration (Mahesh and Greenblatt, 1962). No side effects 
were reported with the one-time administration of the androstenedione, or the transient 
rise in testosterone (Mahesh and Greenblatt, 1962). In the only known study ever to 
investigate the transdermal administration of a testosterone precursor, when the 
androstenedione was administered to the male participants, no rise in serum 
androstenedione, testosterone, or estradiol was reported (Stoppe and Krause, 1986).
The potential for side effects associated with the use of testosterone precursors in females 
is mitigated by the one-time (not chronic) administration of a low dose (66.4 mg) of the 
testosterone precursor. The effects of an acute (one-time) dose of AndrosteDERM® on 
the menstrual cycle are unknown.
4. BENEFITS:
There are no known benefits or improvements for the participant as a result of this 
investigation. However, this study has the potential to contribute to the body of scientific 
knowledge on the subject of testosterone precursor supplementation.
5. RISKS-BENEFITS RATIO: The risks are minimized in this study by using a 
registered nurse, and aseptic technique for all blood drawings. The participants are also 
allowed to stop testing at any time, for any reason. The one-time administration of a low 
dose of the testosterone precursor mitigates the possible side effects associated with it.
The benefits in regard to adding to the body of scientific knowledge on the subject of 
testosterone precursor supplementation and human performance are substantial; thus, the 
risk-benefit ratio for this study is weighted highly in favor of the benefits.
6. COSTS TO SUBJECTS:
There will be no costs to participants except for their time.
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7. INFORMED CONSENT:
Prior to agreeing to participate in this research project, each participant will be given an 
informed consent form (see attached informed consent). After reading the form and 
asking any questions, the individual can decide whether or not to participate. Those 
individuals who choose to participate will be assigned a number based on their informed 
consent; this number will be used for further identification of the participant, thus 
insuring participant anonymity. The informed consents will be collected and stored in a 
locked cabinet in the Sports Injury Research Center at UNLV. Those individuals who 
choose not to participate will I*  excused from the study.
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PRODUCT ANALYSIS
TO: Mark Rasmusstn
COMPANY University of Nevada, Las Vegas
FAX NO: (702) 895-2780
DATE: February 16, 2001
areducl Name; latNumecr: P.O. Number:
AndrosteDERM 2KS1 2LPOCSB362
Analyte Result Unit
Androst-4 ene-3,17-dlone 21.8 A 0.26 mg/ml
Androst-4-ene-38,178-diol 44.61 0.37 mg/ml
asmv ptiformtd by HPLC, idimiOcMlon /  quantification by axtamal ttandarOs method. Standards obtained 
from SttraleMf Inc. Orlefly, the chromatographic condltlono SphcroMrb 00S2 CO (5 mum) column (12.5 cm 
■ 4.0 mm) with a mobile phase (1.2 ml/min) of acetonlMle/1% tnethyiamin# (2:3). Methodology employed 
as published by Class, RL Johnson, El, "Comparison of high-performance Uquld-ehromatographle and go* 
chromatographic analyses of synthetic steroids* as published in ). Liq. Chromatogr., 1993, Vol. 10, No.lO,
PP 3543 3555
This Product Analysis Is subject to our Standard Terms. ÉLJÂS
Oinesh Patel, Ph.D. 
Director of Chemistry
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Androstwwdiofle Raw Data
Sub)ect t1 12 13 14 15 16 t7 t8 t9
Counts'
1 13158 13192 12710 12520 12831 13313 14143 14126 13799
2 10835 3523 11519 11874 11954 11888 11746 11503 12264
3 2054 7970 7772 7944 7366 9803 7983 7530 7290
4 10178 10222 8247 9622 7526 9723 8079 5308 10228
S 4909 8331 8785 8990 9247 8893 8766 7785 8462
6 9887 4232 10574 10809 11168 10247 10433 9622 10099
7 8044 11429 11662 11944 11326 9065 9731 1171 10945
% Bound"
1 55.28107 55.42391 53.39887 52.60062 53.90723 55.93227 59.41938 59.34795 57.97412
2 45.52138 14.80128 48.39509 49.0463 50.22267 49.94538 49.34879 48.32787 51.52508
3 8.829527 33.48458 32.65272 33.37535 30.94698 41.18561 33.5392 31.636 30.62768
4 42.78111 42.94597 34.84835 40.42517 31.81919 40.84951 33.94253 22.30065 42.97118
5 20.82432 35.00126 38.90866 37.76994 38.84968 37.36241 36.82884 32.62331 35.55163
6 41.53853 17.78002 44.42484 44.57188 46.92043 43.051 43.83245 40.42517 42.42921
7 33.79548 48.01697 48.99588 50.18066 47.58424 38.08503 40.88312 4.919755 45.98353
Log"
1 0.225419 0.221063 0.282817 0.30716 0.267314 0.20558 0.09922 0.101398 0.143293
2 0.523043 1.45986 0.435408 0.41555 0.379676 0.388132 0.406325 0.437458 0.339958
3 1.848069 0.890108 0.915476 0.893439 0.967493 0.655263 0.888442 0.946481 0.97723
4 0.607218 0.601581 0.854619 0.878453 0.946993 0.865513 0.878143 1.231165 0.600812
5 1.282285 0.843856 0.78569 0.759425 0.726498 0.771853 0.788124 0.916373 0.827073
6 0.644501 1.369022 0.556482 0.551998 0.480379 0.598378 0.574547 0.678453 0.817339
7 0.880627 0.446939 0.417087 0.380957 0.480136 0.749816 0.664488 1.781199 0.508949
ng/ml*
1 1.880423 1.883653 1.917859 2.028428 1.850607 1.605314 1.256666 1.262985 1.390892
2 3.334592 28.83101 2.725262 2.603452 2.397043 2.444172 2.548736 2.738158 2.187552
3 44.47017 7.7644 8.231439 7.824184 9.278819 4.521297 7.73468 8.840584 9.489206
4 4.047789 3.995587 7.155147 4.78928 8.851022 4.629272 7.5187 17.02804 3.98852
5 19.15512 6.980016 8.105057 5.748788 5.327188 5.91361 8.139373 8.248455 8.715411
6 4.410633 23.38958 3.601489 3.564494 3.022585 3.966227 3.754457 4.76928 4.143233
7 7.596735 2.798589 2.612885 2.404125 2.884931 5.621031 4.618359 57.70311 3.228118
Mean 12.09935 10.77489 4.621277 4.134393 4.801742 4.100132 4.795853 14.37009 4.44899
StdOev 15.42318 10.81059 2.504433 2.110092 3.110421 1.583427 2.46803 19.79957 2.792924
StdE 5.829414 4.086018 0.946587 0.79754 1.175629 0.598479 0.932828 7.483536 1.055628
"Counts.  actual numlMr lacalvsd during radioimmunoassay (not count) 
*% Bound - net countftnaxlmum Itinding count X 100 
"Log • And tag of % Bound
*ng/mi - Actual androstenedione concentration in ng/ml
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Free Testostaront Raw Data
Mean
StdOev
StdE
t1 12 I13 t4 15 t6 17 t8 t9
Counts'
1 19332 22409 22139 22658 21249 21862 21201 19695 20057
2 20735 15625 20830 20682 21108 19805 19756 17700 19668
3 2502 10082 9059 10267 8192 13932 6840 8592 6064
4 15455 12150 10015 11605 6782 15324 10959 12859 14746
5 10708 11557 12498 16161 15126 14667 11542 12462 15058
6 15218 6446 16780 17867 17140 15614 17099 15393 15368
7 13684 18486 19999 19382 17658 14420 14360 5513 14006
% Bound'
1 74.877992 86.79603 85.75025 67.76048 82.30304 64.67736 62.11713 76.28399 77.66611
2 80.312185 60.51979 80.68015 80.1069 81.75691 76.71005 76.52026 88.55682 76.95406
3 9.6909133 39.05028 35.08792 39.76883 31.7298 53.96235 34.23968 33.27911 31.23402
4 59.881337 47.06019 38.79077 44.94926 26.26849 59.35394 42.44713 49.60634 57.11519
5 41.47494 44.76334 48.40809 62.59586 58.58703 56.8092 44.70524 4626865 56.32365
6 58.943373 24.96708 64.99342 69.20366 68.38779 60.47719 68.22899 59.62119 59.60183
7 53.001782 71.60121 77.46146 75.07166 68.39414 55.85251 55.62011 21.35332 54.25672
Log'
1 0.332061 4.029059 0.002628 4)058282 0.10708 0.035138 0.112713 0.289459 0.246974
2 0.1674034 0.767118 0.156254 0.173624 0.123828 0Z76549 0.2823 0.523594 0.269155
3 2.3072474 1.417651 1.537711 1.395939 1.639463 0.965811 1.563413 1.592519 1.654485
4 0.7870697 1.174948 1.425514 1.23891 1.604942 0.602444 1.314725 1.091739 0.870279
5 1.3441827 1.244543 1.1341()6 0.704213 0.625682 0.87955 1.246304 1.138331 0.833662
6 0.6148843 1.844375 0.631566 0.503995 0589318 0.788409 0.594128 0.794346 0.794933
7 0.9949162 0.431348 0.253781 0.326193 0.528523 0.908538 0.91558 1.953873 0.956691
pgMil'
1 2.148132 0.935279 1.006071 0.874416 1.279616 1.08427 1.296323 1.947417 1.765933
2 1.4702914 5.849495 1.433026 1.491501 1.329314 1.89038 1.915578 3.338829 1.85847
3 202.88382 26.18078 34.49142 24.88507 43.59765 9.242951 36.59427 39.13079 45.13207
4 6.1244875 14.96057 26.63875 17.33444 63.81784 6.345181 20.64073 12.35205 7.417882
5 22.089335 17.58075 13.81778 5.060726 6.693938 7.577924 17.63208 13.75091 6.81608
6 6.529566 69.88363 4.281208 3.1915 3.684332 5.666909 3.927808 6.227965 6.236385
7 9.6836229 2.699905 1.793829 2.119302 3.37694 8.100996 8.233417 89.92352 9.055057
35.875608 19.72149 11.89458 7.850994 17.71138 5.729802 12.69143 23.81021 11.18341
73.965056 23.87512 13.65831 9.412404 25.3388 3.111804 12.91642 31.73947 15.22275
27.956163 9.023947 5.161601 3.557554 9.577164 1.176151 4.862703 11.99639 5.75366
‘Counts • actual numlMr received during radkÉnmunoaasay (net count) 
*% Bound • net count/maximum tiinding count X 100 
‘Log • Anti log of % Bound
‘pg/mi • Actual tree testosterone concentration in pg/ml
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Total Tntotlwona Raw Data
SutHect t1 12 13 t4 t5 t6 17 18 t9
Counts*
1 12269 14077 12695 13067 12620 13143 13407 11608 12669
2 11794 9743 11728 11329 11535 11246 10675 10397 10334
3 1390 10692 9265 9374 7181 9490 7632 7180 7038
4 10796 10565 8491 9641 7322 10637 9013 10515 9493
5 9823 4975 10099 11090 10620 10547 9211 9280 10041
6 10151 6458 10774 10501 9917 9161 9272 6539 8203
7 9040 11624 11706 11278 10466 9436 9180 4337 10598
% Bound*
1 81.042341 92.98501 83.85627 88.31349 83.36066 66.81551 68.55935 76.67613 63.68452
2 77.904749 84.35696 77.46879 74.83321 76.19394 74.28496 71.83434 68.67693 68.26078
3 9.181584 70.62554 61.19955 61.91955 47.43378 62.68578 50.41284 47.42717 46.4892
4 71.312504 69.78664 56.08693 63.6832 48.36515 70.26224 59.53498 69.45637 62.70559
5 64.885395 32.86214 66.7085 73.25451 70.14994 69.66775 60.84286 61.29863 66.32538
8 67.051985 42.65804 71.18718 69.36389 65.50631 60.64469 61.24579 56.40399 54.18456
7 59.713323 78.78182 77.32347 74.49633 69.1327 62.32908 60.63809 28.64786 70.00462
Log*
1 1.3821095 1.027275 1.298504 1.225496 1.313223 1.21058 1.158768 1.511836 1.303606
2 1.475332 1.877857 1.488285 1.566592 1.526163 1.582881 1.655693 1.749504 1.761869
3 3.5172005 1.691608 1.971669 1.950276 2.38067 1.927511 2.292158 2.380867 2.408735
4 1.8711975 1.718533 2.123572 1.897876 2.352998 1.702403 2.021126 1.726346 1.926922
5 1.8621566 2.813615 1.807989 1.613498 1.705739 1.720066 1.982267 1.968725 1.819372
6 1.797784 2.522565 1.875515 1.729094 1.843708 1.968154 1.970295 2.114152 2.160095
7 2.0158266 1.508696 1.492603 1.576601 1.735963 1.936108 1.988351 2.938828 1.710057
ng/dr
1 24.105131 10.64817 1988399 16.80721 20.56946 16.23977 14.41345 32.49846 20.11899
2 29.87666 75.48441 30.78117 36.86311 33.58635 38.27202 45.25777 56.17001 57.79214
3 3290.0346 49.1596 9368468 89.18184 240.2538 64.62731 195.9557 240.3624 256.2921
4 46.902668 52.06347 132.9145 79.04521 225.4228 50.39675 104.9846 53.25324 64.51265
5 72.804228 651.0517 64.2672 41.06745 50.78541 52.4687 95.99896 93.05178 65.97393
6 62.774602 333.0925 47.37129 53.59122 69.77637 97.30928 93.38879 130.0624 151.3891
7 103.71143 32.26234 31.08871 37.72256 54.44559 66.71784 97.35326 8686165 51.29283
Mean 516.60133 171.966 59.99879 50.61123 99.26283 60.86453 92.47893 210.5733 98.19596
StdOev 1222.3861 237.9748 40.67712 25.47544 92.67231 29.56011 56.60517 298.4691 60.5996
Std E 462.01852 89.94603 15.37451 9.628811 35.02684 11.17267 21.39474 112.8107 30.46378
'Counta • actual numlwr racalvad diaing radjoinununcastay (net count) 
*% Bound • net count/maittmNn tiinding count X 100 
*Log • And log of % Bound
"ng/dl • Actual total taatoetemne concentration in ng/dl
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